STAT3 Hyper-IgE Syndrome is a primary immunodeficiency caused by dominant-negative mutations in the STAT3 gene, presenting in early childhood with markedly elevated serum IgE, recurrent staphylococcal skin abscesses, pneumonias with pneumatocele formation, eczema, and characteristic connective tissue and skeletal abnormalities including retained primary teeth and pathologic fractures.

Autosomal Dominant Hyper-IgE Syndrome)

STAT3 Hyper-IgE Syndrome (STAT3-HIES), historically known as Job syndrome (a biblical allusion to Job who was "smote with boils"), is a combined immunodeficiency with associated or syndromic features ^[1]^[2] — a rare, multisystem primary immunodeficiency disorder (PID) / inborn error of immunity (IEI) caused by autosomal dominant (AD), loss-of-function (LOF) mutations in the STAT3 gene ^[1]^[2].

Breaking down the name:

STAT3 = Signal Transducer and Activator of Transcription 3 — a transcription factor that sits downstream of multiple cytokine receptors (IL-6, IL-10, IL-21, IL-22, IL-23, etc.)
Hyper-IgE = pathologically elevated serum IgE levels (typically > 2000 IU/mL)
Syndrome = multisystem disease affecting immunity, connective tissue, skeleton, dentition, and vasculature

The disease is characterised by a clinical triad:

Recurrent Staphylococcal skin abscesses (classically "cold" — lacking the expected warmth, erythema, and tenderness)
Recurrent pneumonia with pneumatocele formation
Markedly elevated serum IgE

But STAT3-HIES is far more than an immunodeficiency — it is a multi-system connective tissue and immune dysregulation disorder because STAT3 signalling is critical in bone metabolism, vascular remodelling, wound healing, and dental development.

IUIS Classification

Under the International Union of Immunological Societies (IUIS) 2022 classification, STAT3-HIES falls under Category 2: Combined immunodeficiencies with associated or syndromic features ^[1]^[2]. This is because while the primary immune defect involves T-cells (specifically Th17), it presents alongside non-immunological syndromic features (skeletal, dental, connective tissue abnormalities).

Parameter	Detail
Incidence	Extremely rare; estimated ~1 in 100,000 live births (varies by study)
Sex ratio	Equal male:female (autosomal dominant inheritance)
Ethnic predilection	No specific ethnic predilection; reported across all ethnicities including Chinese populations in Hong Kong
Age at presentation	Typically presents in infancy to early childhood (neonatal eczematous rash within the first few weeks of life, recurrent infections by 1–2 years of age)
Inheritance	Autosomal dominant (AD) — both de novo mutations (~60–70%) and familial cases (~30–40%) ^[1]^[2]
Genetic basis	STAT3 gene (chromosome 17q21.2), loss-of-function (dominant-negative) mutations ^[1]^[2]

In Hong Kong, PIDs are diagnosed and followed at tertiary centres (particularly Queen Mary Hospital and Prince of Wales Hospital). STAT3-HIES cases are rare but well-recognised, and Hong Kong has contributed to international PID registries. Newborn screening for SCID (via TREC) has been implemented, but STAT3-HIES is not detected by TREC/KREC newborn screening — it requires clinical recognition.

Since this is a monogenic inherited disorder, "risk factors" per se are genetic:

Family history of STAT3-HIES — autosomal dominant; an affected parent has a 50% chance of passing the mutation to each child
De novo mutation — the majority of cases (~60–70%) arise spontaneously with no family history
There are no environmental or modifiable risk factors — the disease is entirely determined by the STAT3 genotype

Key Point for History

When you see a child with recurrent staphylococcal "cold" abscesses + eczema-like rash from infancy + retained primary teeth + characteristic facies + pneumatoceles → think STAT3-HIES. Always ask about family history of similar features (coarse facies, frequent skin infections, retained teeth, scoliosis, fractures with minimal trauma).

4. Anatomy and Function: The STAT3 Signalling Pathway

STAT3 (Signal Transducer and Activator of Transcription 3) is a cytoplasmic transcription factor that is activated by JAK-STAT signalling downstream of numerous cytokine and growth factor receptors. It is one of a family of 7 STAT proteins (STAT1–4, STAT5a, STAT5b, STAT6).

Cytokine binds receptor → Receptor-associated JAK kinases phosphorylate each other
→ Phosphorylated JAKs phosphorylate receptor intracellular domains
→ STAT3 monomers dock on phosphorylated receptor → JAK phosphorylates STAT3 on Tyr705
→ Phosphorylated STAT3 dimerises (forms homodimer or heterodimer)
→ Dimer translocates to nucleus → Binds DNA promoter elements → Activates target gene transcription

This is critical because it explains the multi-system nature of the disease:

Cytokine	Normal Function	Consequence of STAT3 LOF
IL-6	Acute phase response, B-cell differentiation, Th17 differentiation	Impaired acute phase response (CRP often fails to rise during infection → "cold" abscesses)
IL-10	Anti-inflammatory, immune regulation	Paradoxically, some immune dysregulation
IL-11	Bone remodelling, dental development	Skeletal abnormalities, retained primary teeth
IL-21	B-cell class switching, germinal centre reactions	Impaired memory B-cell formation, poor vaccine responses
IL-22	Epithelial antimicrobial defence (skin, lung, gut)	Impaired epithelial barrier → mucocutaneous candidiasis, susceptibility to skin infections
IL-23	Th17 differentiation and maintenance	Markedly reduced Th17 cells → susceptibility to extracellular bacteria (Staph aureus) and fungi (Candida, Aspergillus) ^[1]^[2]
IL-27	Anti-inflammatory, Th1 regulation	Immune dysregulation
EGF, PDGF, VEGF	Growth, angiogenesis, wound healing	Vascular abnormalities (coronary artery aneurysms, cerebral aneurysms)
Leptin	Energy homeostasis	May contribute to body habitus

The hallmark immunological defect in STAT3-HIES is a profound reduction in Th17 cells ^[1]^[2].

Why Th17 cells matter:

Th17 cells produce IL-17A, IL-17F, and IL-22
IL-17 recruits neutrophils to sites of infection and induces epithelial cells to produce antimicrobial peptides (β-defensins, S100 proteins)
IL-22 strengthens epithelial barrier function and induces antimicrobial peptides
Th17 cells are the primary adaptive immune defence against extracellular bacteria (especially Staphylococcus aureus) and fungi (especially Candida and Aspergillus)

When STAT3 is dysfunctional:

Naïve CD4+ T cells cannot differentiate into Th17 cells (because IL-6 + TGF-β → STAT3 activation is required for RORγt expression, the master Th17 transcription factor)
This leads to severely impaired mucocutaneous defence → recurrent skin abscesses, pneumonias, and candidiasis

The mechanism of hyper-IgE is not fully elucidated but involves:

Impaired IL-21 signalling → defective B-cell class switching from IgE to other isotypes (IL-21 normally promotes switching away from IgE)
Impaired IL-10 signalling → loss of regulatory feedback that would normally suppress IgE production
Dysregulated Th2 responses → in the absence of Th17 counterbalancing, there is a relative skewing toward Th2 and IgE production

The IgE itself is largely non-specific (polyclonal) and does not mediate the clinical infections. It is a biomarker, not a pathogenic driver. Patients with STAT3-HIES do NOT typically present with allergic disease (anaphylaxis, allergic rhinitis) despite sky-high IgE — this is because the IgE is not directed against specific allergens in a functional way.

High Yield Concept

High IgE ≠ allergy. The elevated IgE in STAT3-HIES is polyclonal and non-functional. This is an important distinction from atopic conditions. As noted in the allergy lecture: "Atopy = create more IgE → but this does not mean the IgE does anything → high levels of IgE does not equal allergy" ^[3]. In STAT3-HIES, the IgE elevation is a marker of dysregulated class switching, not allergic sensitisation.

5. Aetiology and Pathophysiology

STAT3 gene: Chromosome 17q21.2, autosomal dominant, loss-of-function (dominant-negative) mutations ^[1]^[2].

Feature	Detail
Gene	STAT3
Locus	17q21.2
Inheritance	Autosomal dominant ^[1]^[2]
Mutation type	Loss-of-function (dominant-negative) — the mutant STAT3 protein dimerises with wild-type STAT3 and poisons its function ^[1]^[2]
Hotspot domains	SH2 domain and DNA-binding domain are most commonly affected
De novo vs inherited	~60–70% de novo, ~30–40% inherited

Why dominant-negative?

STAT3 functions as a dimer (two STAT3 molecules must come together)
Even with one normal copy of the gene, the mutant STAT3 produced by the other allele can dimerise with wild-type STAT3, creating a non-functional heterodimer
This means that only ~25% of dimers are wild-type/wild-type → >75% reduction in functional STAT3 dimers
This is why a single mutant allele (heterozygous) causes disease — a classic dominant-negative mechanism

5.2 Pathophysiology: Connecting Genotype to Phenotype

The multi-system manifestations are explained by STAT3's role in numerous signalling pathways:

Defect	Mechanism	Clinical Manifestation
Th17 deficiency	IL-6/IL-23 → STAT3 → RORγt required for Th17 differentiation; STAT3 LOF blocks this pathway	Recurrent Staph aureus skin abscesses, pneumonias; mucocutaneous candidiasis; invasive fungal infections (Aspergillus) ^[1]^[2]
Impaired neutrophil chemotaxis	Th17-derived IL-17 normally recruits neutrophils; also STAT3 directly involved in neutrophil chemotaxis	"Cold" abscesses — abscesses that lack the expected warmth, redness, and pain because neutrophils fail to arrive adequately
Poor acute phase response	IL-6 → STAT3 → CRP and other acute phase proteins; impaired in STAT3-HIES	CRP often fails to rise during serious infection; fever may be absent → infections appear deceptively non-severe
Impaired memory B-cell generation	IL-21 → STAT3 required for germinal centre B-cell reactions and memory B-cell formation	Poor vaccine responses; may need IVIG supplementation
Dysregulated IgE class switching	IL-21/IL-10 → STAT3 normally inhibits excessive IgE; loss of this regulation	Markedly elevated serum IgE (often > 2000 IU/mL)
Eosinophilia	Dysregulated Th2 skewing and impaired regulation	High absolute eosinophil count ^[2]

Feature	Mechanism	Clinical Manifestation
Characteristic facies	STAT3 involved in craniofacial development (possibly via IL-6/IL-11 signalling in bone remodelling)	Coarse facies: prominent forehead, deep-set eyes, broad nasal bridge, wide fleshy nose, rough skin texture
Retained primary teeth	IL-11 → STAT3 required for osteoclast-mediated resorption of primary tooth roots; without this, roots are not resorbed and teeth are not shed	Retained deciduous teeth; double rows of teeth (primary + permanent)
Skeletal abnormalities	STAT3 involved in osteoclast/osteoblast signalling via IL-6/IL-11; also possibly TGF-β signalling	Scoliosis; minimal-trauma fractures (osteoporosis); craniosynostosis; hyperextensible joints
Pneumatoceles	Impaired tissue remodelling and wound healing after pneumonia (STAT3 involved in matrix metalloproteinase regulation)	Persistent lung cysts (pneumatoceles) after pneumonia → become superinfected with Pseudomonas, NTM ^[1]^[2]
Vascular abnormalities	STAT3 involved in VEGF signalling and vascular smooth muscle maintenance	Coronary artery aneurysms, cerebral aneurysms, middle-sized artery tortuosity
Connective tissue abnormalities	STAT3 involved in extracellular matrix maintenance	Hyperextensibility of joints, thin/elastic skin

Why 'Job Syndrome'?

The biblical figure Job was afflicted by God with painful boils from the soles of his feet to the crown of his head. The original description by Davis et al. in 1966 described two girls with recurrent "cold" staphylococcal abscesses, eczematoid dermatitis, and pneumonia — they nicknamed the condition "Job's syndrome." The name stuck, though the formal designation is now STAT3-HIES.

6. Classification

STAT3-HIES is classified under Category 2: Combined immunodeficiencies with associated or syndromic features ^[1]^[2].

This is the same category as:

Wiskott-Aldrich syndrome
DiGeorge syndrome (22q11.2 deletion)
Ataxia-telangiectasia

STAT3-HIES is the most common and best-characterised form of HIES, but other genetic causes exist:

Syndrome	Gene	Inheritance	Key Distinguishing Features
STAT3-HIES (AD-HIES)	STAT3	AD (LOF, dominant-negative)	Cold Staph abscesses, pneumatoceles, eczema, retained teeth, coarse facies, scoliosis, fractures ^[1]^[2]
DOCK8 deficiency (AR-HIES)	DOCK8	AR (LOF)	Severe viral infections (HSV, HPV, molluscum), food allergies, CNS vasculitis, malignancy risk; NO pneumatoceles or skeletal features
PGM3 deficiency	PGM3	AR	Neurocognitive impairment, autoimmunity
IL6ST (GP130) deficiency	IL6ST	AR	Overlaps with STAT3-HIES phenotype (as GP130 signals through STAT3)
IL6R deficiency	IL6R	AR	Similar to STAT3-HIES phenotype
ZNF341 deficiency	ZNF341	AR	Resembles STAT3-HIES (ZNF341 is a transcription factor for STAT3 expression)
ERBIN deficiency	ERBIN	AD	Hyper-IgE, dermatitis, infections

STAT3-HIES vs DOCK8 Deficiency

A common exam pitfall: students confuse the two main forms of HIES.

STAT3-HIES (AD): Cold Staph abscesses, pneumatoceles, skeletal/dental/facial features, NO severe viral infections

DOCK8 deficiency (AR): Severe viral infections (extensive molluscum, HPV, HSV), food allergies, eczema herpeticum, NO pneumatoceles or skeletal features

The presence or absence of pneumatoceles and skeletal/connective tissue features differentiates STAT3-HIES from DOCK8 deficiency.

7. Clinical Features

Age	Typical Presenting Features
Neonate (0–28 days)	Eczematoid/papulopustular rash within first weeks of life (often misdiagnosed as neonatal acne or eczema)
Infant (1–12 months)	Recurrent skin abscesses (often Staph aureus); eczema-like dermatitis; oral candidiasis
Early childhood (1–5 years)	Recurrent pneumonia (Staph, Haemophilus); pneumatocele formation; "cold" abscesses; characteristic facies becoming apparent
Later childhood (5–12 years)	Retained primary teeth; fractures with minimal trauma; scoliosis emerging
Adolescence	Full phenotype: coarse facies, scoliosis, joint hyperextensibility; ongoing infections; pneumatoceles may superinfect

7.2 Symptoms (with Pathophysiological Basis)

Recurrent skin abscesses and boils
- Typically "cold" — lacking the expected warmth, erythema, tenderness, and fluctuance ^[1]^[2]
- Why "cold"? → STAT3 LOF → impaired IL-6 signalling → poor acute phase response → CRP does not rise, inflammatory cytokines not produced → poor neutrophil recruitment → the usual signs of inflammation (rubor, calor, dolor, tumor) are attenuated
- Almost always caused by Staphylococcus aureus ^[1]^[2]
- Can occur anywhere on the body; face, neck, and scalp are common
Recurrent pneumonia
- Episodes of pneumonia, often from early infancy
- Caused by S. aureus, Streptococcus pneumoniae, Haemophilus influenzae ^[1]^[2]
- Why recurrent? → Th17 deficiency → impaired neutrophil recruitment to airways → impaired mucosal defence → bacteria can establish infection
- Complications: pneumatocele formation (see below)
Chronic mucocutaneous candidiasis (CMC)
- Oral thrush, nail candidiasis, vaginal candidiasis
- Why? → Th17 cells are the critical defence against mucosal Candida; IL-17 and IL-22 produced by Th17 cells induce antifungal peptides from epithelial cells → STAT3 LOF → Th17 deficiency → Candida overgrows on mucosal surfaces
Invasive fungal infections
- Aspergillus is particularly feared, especially superinfection of pneumatoceles ^[1]
- Coccidioides, Histoplasma, and Pneumocystis jirovecii may also occur
- Why fungi? → Th17 deficiency impairs the primary adaptive immune response against fungi
Eczematoid dermatitis / Papulopustular rash
- Often the earliest manifestation (within first weeks of life)
- Can be mistaken for atopic eczema or neonatal acne
- Distribution: face, scalp, diaper area (neonates); generalised in older children
- Why? → Multifactorial: impaired skin barrier (IL-22 deficiency), dysregulated immune response, superinfection with Staph aureus
- Histologically may show eosinophilic infiltration
Recurrent upper respiratory tract infections and sinusitis
- Chronic sinusitis is common
- Otitis media may occur but is less prominent than in pure antibody deficiencies

Failure of primary teeth to exfoliate (retained deciduous teeth)
- Children report that "baby teeth won't fall out" → permanent teeth erupt alongside or behind primary teeth → "double rows" of teeth
- Why? → IL-11 → STAT3 pathway is required for osteoclast activation → osteoclasts resorb the roots of primary teeth, allowing them to shed → STAT3 LOF → impaired osteoclast function → roots not resorbed → teeth retained
Fractures with minimal trauma / Bone pain
- Pathological fractures from minor falls; long bone fractures most common
- Why? → STAT3 involved in osteoblast/osteoclast balance and bone remodelling → reduced bone mineral density (osteopenia/osteoporosis) → bones are fragile
Scoliosis
- Progressive, may require surgical correction
- Why? → STAT3 signalling through IL-6/IL-11 pathways is involved in vertebral body and intervertebral disc development and maintenance
Joint hyperextensibility / Hypermobility
- Patients may report frequent joint sprains or "loose" joints
- Why? → STAT3 involved in connective tissue (collagen, extracellular matrix) maintenance → impaired matrix integrity → joint laxity
Vascular symptoms (typically in adolescence/adulthood)
- Coronary artery aneurysms, cerebral (berry) aneurysms, middle-sized artery tortuosity
- Risk of stroke, myocardial infarction at young ages
- Why? → STAT3 involved in vascular smooth muscle cell maintenance and VEGF-mediated vascular remodelling → vessel wall weakness → aneurysm formation

7.3 Signs (with Pathophysiological Basis)

Sign	Description	Pathophysiological Basis
Characteristic ("coarse") facies	Prominent forehead (frontal bossing), deep-set eyes, broad nasal bridge, wide fleshy nose, rough/porous skin, facial asymmetry	STAT3 involved in craniofacial bone development; impaired remodelling leads to these characteristic features; facies become more pronounced with age
Neonatal papulopustular rash / Eczematoid dermatitis	Erythematous papules and pustules, often eosinophil-rich on biopsy; may resemble eczema or neonatal acne	Impaired skin barrier (IL-22 deficiency) + dysregulated immune response + secondary Staph infection
Scars from previous abscesses/infections	Multiple healed scars on skin, often over face, neck, scalp	Consequence of recurrent "cold" staphylococcal abscesses

Sign	Description	Pathophysiological Basis
"Cold" staphylococcal abscesses	Fluctuant masses with minimal surrounding erythema, warmth, and tenderness — disproportionately painless for their size	Impaired IL-6 → STAT3 acute phase response → poor inflammatory cytokine production → defective neutrophil chemotaxis → muted inflammatory signs
Eczematoid dermatitis	Lichenified, excoriated patches (chronic); papulopustular in acute phase; often involves face, extensor surfaces, and trunk	Th17/IL-22 deficiency → impaired skin barrier → susceptibility to eczematous inflammation and superinfection
Oral candidiasis (thrush)	White plaques on buccal mucosa, tongue	Th17 deficiency → impaired mucosal antifungal defence
Nail candidiasis (onychomycosis)	Thickened, dystrophic nails	Th17/IL-22 deficiency → impaired nail bed defence

Sign	Description	Pathophysiological Basis
Retained primary teeth	Deciduous teeth still present well beyond expected age of exfoliation; permanent teeth may erupt in abnormal positions → "double rows"	IL-11 → STAT3 → osteoclast activation required for root resorption of primary teeth; STAT3 LOF → impaired resorption → retention
High-arched palate	Narrow, high palate	Craniofacial skeletal abnormality from impaired STAT3-mediated bone development

Sign	Description	Pathophysiological Basis
Scoliosis	Lateral curvature of spine, may be progressive	Impaired STAT3 signalling in vertebral development and maintenance
Pathological fractures	Fractures from minimal trauma; may present with deformity or tenderness	Reduced bone mineral density from impaired STAT3 → osteoblast/osteoclast signalling
Joint hyperextensibility	Beighton score may be elevated; "double-jointed"	Connective tissue laxity from impaired STAT3-mediated extracellular matrix maintenance
Craniosynostosis	Premature fusion of cranial sutures (rare)	Impaired craniofacial bone development

Sign	Description	Pathophysiological Basis
Pneumatoceles on CXR/CT	Persistent air-filled cysts in lung parenchyma, often following pneumonia episodes ^[1]^[2]	Impaired tissue repair after pneumonia: STAT3 involved in MMP regulation and wound healing → post-pneumonic parenchymal destruction not properly repaired → cyst formation
Bronchiectasis	Dilated, thickened bronchi (if chronic/recurrent lower respiratory infections)	Chronic infection → airway wall destruction
Signs of superinfection of pneumatoceles	Fever, cough, haemoptysis; air-fluid levels in cysts	Pneumatoceles become colonised by Pseudomonas aeruginosa, non-tuberculous mycobacteria (NTM), or Aspergillus

Sign	Description	Pathophysiological Basis
Coronary artery aneurysms	Usually asymptomatic until complication (MI)	STAT3 → VEGF/EGF signalling impaired → vessel wall weakening → aneurysmal dilatation
Cerebral aneurysms	Risk of subarachnoid haemorrhage	Same vascular wall defect
Arterial tortuosity	Tortuous medium-sized arteries on imaging	Connective tissue defect in vessel walls

The NIH Clinical Scoring System (Grimbacher et al., 1999; updated) is used to quantify the clinical probability of STAT3-HIES before genetic testing is available. It assigns points based on clinical and laboratory features:

Feature	Points
Highest serum IgE (> 2000 IU/mL)	10
Skin abscesses	4–8
Pneumonia (frequency)	4–8
Pneumatoceles	8
Retained primary teeth (≥ 3)	8
Scoliosis (maximal curvature)	6
Fractures with minimal trauma	4
Characteristic facies	5
Eczema (worst)	4
Upper airway infections	2–4
Candidiasis	4
Newborn rash	4
Other serious infections	4
Hyperextensibility	4
Lymphoma	4
High palate	2
Young age correction	Variable

Score ≥ 40: Highly suggestive of STAT3-HIES → proceed to genetic testing
Score 20–40: Possible STAT3-HIES → consider genetic testing
Score < 20: Unlikely

Note: This scoring system is most useful in children old enough to have developed the syndromic features. In infants, the score may be low despite having the genetic mutation — genetic testing is the gold standard.

Immunological Features	Non-Immunological (Syndromic) Features
Recurrent "cold" Staph aureus abscesses	Characteristic coarse facies
Eczematoid dermatitis (neonatal onset)	Retained primary teeth
Recurrent pneumonia → pneumatoceles	Pathological fractures / Osteoporosis
Chronic mucocutaneous candidiasis	Scoliosis
Invasive fungal infections (Aspergillus)	Joint hyperextensibility
Markedly elevated IgE	Vascular aneurysms (coronary, cerebral)
Elevated eosinophil count ^[2]	Craniosynostosis
Impaired memory B-cell generation	High-arched palate

This will be covered in detail in Part 2, but key lab findings include:

Serum IgE markedly elevated (often > 2000 IU/mL, sometimes > 50,000 IU/mL) ^[1]^[2]
High absolute eosinophil count ^[2]
Low/absent Th17 cells on flow cytometry
CXR: Pneumatoceles ("massive pneumatoceles" on CXR is a classic exam finding) ^[2]
Normal or near-normal total lymphocyte count (unlike SCID)
May have poor specific antibody responses despite normal immunoglobulin levels (IgG, IgA, IgM may be normal or low-normal)

Classic Exam Vignette

A 3-year-old boy presents with recurrent "cold" skin abscesses that grow Staphylococcus aureus, a chronic eczema-like rash since infancy, and a CXR showing pneumatoceles. On examination, he has a coarse facies with a broad nose and prominent forehead. Serum IgE is 15,000 IU/mL with eosinophilia. His mother notes he still has all his baby teeth.

→ Think STAT3-HIES (Job Syndrome) → Confirm with flow cytometry (low Th17 cells) and genetic testing (STAT3 mutation) → Treatment: Septrin (prophylactic TMP-SMX) + IVIG + anti-IL-17 (secukinumab) considered in refractory cases ^[2]

STAT3-HIES is rare worldwide and similarly rare in Hong Kong
Cases are managed at Queen Mary Hospital (Department of Paediatrics and Adolescent Medicine, under Prof. YL Lau's team) and other tertiary centres
Newborn screening (NBS) in Hong Kong currently screens for SCID (via TREC) — STAT3-HIES is NOT detected by NBS (TREC is normal because T-cell development is largely intact; it is Th17 differentiation that is impaired)
Hong Kong patients have access to genetic testing (next-generation sequencing panels for PIDs, or whole-exome sequencing)
IVIG is available through Hospital Authority
Secukinumab (anti-IL-17A monoclonal antibody) and dupilumab (anti-IL-4Rα) have been used in selected cases
HSCT (haematopoietic stem cell transplantation) has been performed for STAT3-HIES in some centres globally, but outcomes are variable and it is not yet standard of care — this differs from DOCK8 deficiency where HSCT is curative and recommended
Climate considerations: Hong Kong's hot, humid climate may exacerbate skin infections and eczematoid dermatitis in these patients

High Yield Summary

STAT3 Hyper-IgE Syndrome (STAT3-HIES / Job Syndrome)

Definition: Autosomal dominant, loss-of-function (dominant-negative) mutation in STAT3 → multisystem PID with syndromic features
IUIS Category: Combined immunodeficiency with associated/syndromic features (Category 2)
Core Immunological Defect: Th17 deficiency → susceptibility to Staph aureus (cold abscesses), fungi (Candida, Aspergillus)
Classic Triad: Recurrent cold Staph abscesses + Recurrent pneumonia with pneumatoceles + Markedly elevated IgE
Key Lab Findings: IgE > 2000 IU/mL, eosinophilia, low Th17 cells, CXR pneumatoceles
Syndromic Features: Coarse facies, retained primary teeth, scoliosis, pathological fractures, joint hyperextensibility, vascular aneurysms
Why "cold" abscesses? → IL-6/STAT3 impairment → poor acute phase response → poor neutrophil chemotaxis → muted inflammation
Why pneumatoceles? → Impaired tissue repair post-pneumonia (STAT3 involved in wound healing/MMP regulation)
Why retained teeth? → IL-11/STAT3 → osteoclast activation for root resorption impaired
Treatment: Prophylactic antibiotics (TMP-SMX) + antifungals (itraconazole/voriconazole) + IVIG + consider secukinumab; skin care; dental extraction of retained teeth; fracture prevention
Key Distinction: STAT3-HIES (AD) has pneumatoceles and skeletal features; DOCK8 deficiency (AR) has severe viral infections — do NOT confuse them

Active Recall - STAT3 Hyper-IgE Syndrome (Definition, Aetiology, Clinical Features)

^[1] Lecture slides: GC 144. A child with recurrent infections Primary immunodeficiencies.pdf; Block C - A child with recurrent infections_ Primary immunodeficiencies.pdf ^[2] Senior notes: Jerry's immunodeficiencies.pdf (Block A and Block C sections) ^[3] Senior notes: Block A - Fundamentals of Allergology.pdf (p3) ^[4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p638) ^[5] AOS material: AOS - Paeds.pdf (Q9) ^[6] Lecture slides: Investigations of Imm Disorders 2025.pdf

Differential Diagnosis of STAT3 Hyper-IgE Syndrome

STAT3-HIES is a multi-system disorder, so it masquerades as several different conditions depending on which feature is most prominent at presentation. A neonate may look like "severe eczema"; a toddler may look like "recurrent staphylococcal skin infection"; a school-age child may present with "recurrent pneumonia and high IgE" and be labelled "severe atopic asthma." The key is recognising the constellation of features — no single feature is pathognomonic, but the combination is.

The differential diagnosis therefore organises around three clinical axes — the clinician must consider all three simultaneously:

Recurrent infections (especially Staph aureus, Candida, Aspergillus) → other primary immunodeficiencies
Markedly elevated IgE + eczematoid dermatitis + eosinophilia → other causes of hyper-IgE and eczema
Skeletal/connective tissue/dental abnormalities → connective tissue disorders

3. Systematic Differential Diagnosis

3.1 Other Primary Immunodeficiencies with Elevated IgE

These are the most important differentials because they share the "hyper-IgE" phenotype. The exam frequently tests the ability to distinguish between them.

Feature	DOCK8 Deficiency	STAT3-HIES
Gene / Inheritance	DOCK8, autosomal recessive	STAT3, autosomal dominant ^[1]^[2]
IgE level	Very high	Very high
Eczema	Severe, often refractory	Present from infancy
Infections	Severe viral infections: extensive molluscum contagiosum, HPV (warts), HSV (eczema herpeticum), VZV	"Cold" Staph aureus abscesses, Candida, Aspergillus ^[1]^[2]
Pneumatoceles	Absent	Present — classic finding ^[2]
Skeletal features	Absent (no scoliosis, no fractures, no retained teeth)	Present (scoliosis, fractures, retained teeth, coarse facies)
Malignancy risk	High (squamous cell carcinoma, lymphoma)	Moderate (lymphoma)
Food allergy / Anaphylaxis	Common and severe	Uncommon despite sky-high IgE
CNS disease	CNS vasculitis, strokes	Cerebral aneurysms (different mechanism)
Treatment	HSCT is curative and recommended	HSCT outcomes variable; prophylaxis-based approach

High Yield Exam Distinction

DOCK8 deficiency = severe viral infections, NO pneumatoceles, NO skeletal features. STAT3-HIES = "cold" Staph abscesses, pneumatoceles, skeletal/dental/facial syndromic features. This is arguably the single most important differential distinction for HIES on a paediatrics exam ^[1]^[2].

Why does DOCK8 deficiency cause viral infections but STAT3-HIES does not?

DOCK8 (Dedicator of Cytokinesis 8) is critical for T-cell and NK-cell cytoskeletal reorganisation during the immunological synapse — without it, cytotoxic T-cells and NK cells cannot effectively kill virus-infected cells
STAT3, by contrast, primarily affects Th17 differentiation — Th17 cells defend against extracellular bacteria and fungi, not viruses
Therefore, the spectrum of infections reflects the specific immune arm that is impaired

WAS is a combined immunodeficiency with associated/syndromic features ^[1]^[2] — same IUIS category as STAT3-HIES.

Feature	WAS	STAT3-HIES
Gene / Inheritance	WAS gene, X-linked recessive	STAT3, AD
Classic triad/tetrad	Eczema + microthrombocytopenia (low AND small platelets) + immunodeficiency ± bloody diarrhoea ^[2]	Cold abscesses + pneumatoceles + elevated IgE
Platelet count	Low, with characteristically SMALL platelets (low MPV) ^[2]	Normal
IgM	Low ^[2]	Normal or variable
IgE	May be elevated	Markedly elevated
Bleeding	Bloody diarrhoea, petechiae, mucosal bleeding (from thrombocytopenia)	Not a feature
Eczema	Present (can be severe)	Eczematoid dermatitis (present)
Skeletal/dental features	Absent	Present

Why is WAS X-linked? → The WAS protein (WASp) is expressed in haematopoietic cells and is critical for actin cytoskeletal reorganisation. The gene is on the X chromosome, so affected individuals are almost always male.

Why are the platelets small? → WASp deficiency impairs platelet cytoskeletal integrity → platelets are structurally abnormal, small, and rapidly destroyed → microthrombocytopenia (this is virtually pathognomonic — most other causes of thrombocytopenia in children produce normal or large platelets).

Exam tip from AOS Q9 ^[5]: A child with recurrent cervical lymphadenitis growing Staph aureus, enlarged BCG scar, perianal sepsis, hepatosplenomegaly, normal CBC but high IgG → this is chronic granulomatous disease (CGD), NOT HIES. The key distinguishing features are: normal IgE (not elevated), granuloma formation, catalase-positive organisms, and enlarged BCG scar suggesting BCG dissemination.

CGD must be differentiated because it also presents with recurrent Staph aureus abscesses and skin infections in young children ^[5]^[6].

Feature	CGD	STAT3-HIES
Gene / Inheritance	CYBB (X-linked, 60%) or AR (CYBA, NCF1, NCF2, NCF4) ^[2]	STAT3, AD
Mechanism	Phagocytes lack NADPH oxidase → cannot produce reactive oxygen species (ROS) → cannot kill catalase-positive organisms ^[2]^[6]	STAT3 LOF → Th17 deficiency
Key pathogens	Catalase-positive: Staph aureus, Aspergillus, Serratia, Nocardia, Burkholderia cepacia	Staph aureus, Candida, Aspergillus
Abscesses	"Hot" abscesses — full inflammatory response (neutrophils arrive but cannot kill) with granuloma formation	"Cold" abscesses — muted inflammatory response
BCG vaccination	BCG dissemination (enlarged BCG scar, regional lymphadenitis) ^[5]^[6]	BCG usually tolerated
Granulomas	Present — hallmark feature (chronic inflammation → granuloma)	Absent
IgE	Normal	Markedly elevated
IgG	May be elevated ^[5]	Normal or variable
Hepatosplenomegaly	Common (from granulomatous infiltration) ^[5]	Uncommon
Skeletal/dental features	Absent	Present
CBC	Usually normal ^[5]	Usually normal (± eosinophilia)

Why "hot" abscesses in CGD but "cold" in STAT3-HIES?

In CGD, neutrophils arrive at the infection site (chemotaxis is intact) but cannot kill the ingested organisms (NADPH oxidase defect) → full inflammatory response with pus → "hot" abscesses that progress to granulomas
In STAT3-HIES, the IL-6/STAT3 acute phase pathway is impaired AND Th17-driven neutrophil chemotaxis is impaired → neutrophils do not arrive adequately → muted inflammation → "cold" abscesses

Feature	LAD	STAT3-HIES
Mechanism	Deficiency of CD18 (β2-integrin) → neutrophils cannot adhere to endothelium → cannot leave bloodstream ^[6]	Th17 deficiency
Neutrophil count	Markedly elevated (trapped in blood) ^[6]	Normal
Pus formation	Absent (no neutrophils at tissue level) ^[6]	Reduced but not absent
Classic presentation	Delayed umbilical cord separation + omphalitis; poor wound healing ^[6]	Neonatal eczematoid rash → cold abscesses
IgE	Normal	Markedly elevated

Why is the neutrophil count HIGH in LAD? → Neutrophils are produced normally by the bone marrow and released into blood, but they cannot stick to the vessel wall (no CD18 adhesion molecule) → they remain circulating → peripheral blood neutrophilia. Meanwhile, tissues are devoid of neutrophils → infections without pus.

Feature	SCID	STAT3-HIES
Inheritance	Most common: IL2RG (X-linked) ^[2]	STAT3, AD
Cells affected	Both T-cells AND B-cells ^[2]	Primarily Th17 cells
Lymphocyte count	Very low (< 2500/µL in infants) ^[2]^[4]	Normal
Infections	ALL organisms: bacteria, viruses, fungi, PJP, BCG dissemination ^[2]	Staph, Candida, Aspergillus
IgE	Low (all immunoglobulins low)	Markedly elevated
Thymic shadow on CXR	Absent ^[2]^[4]	Present
Age at presentation	Very early infancy (first weeks to months of life); failure to thrive ^[4]	Infancy onwards but less fulminant
Prognosis without treatment	Fatal within first year if untreated	Chronic disease; survival into adulthood

SCID is usually distinguishable from STAT3-HIES because SCID presents much earlier and more severely, with failure to thrive and susceptibility to virtually all classes of pathogens. The lymphocyte count is a critical differentiator — lymphopenia in infants (< 2500 cells/µL) should raise concern for SCID ^[4].

Feature	HIGM Type 1 (most common)	STAT3-HIES
Gene / Inheritance	CD40L (X-linked) ^[2]	STAT3, AD
Mechanism	Cannot perform class-switch recombination (IgM → IgG/IgA/IgE)	Th17 deficiency + dysregulated IgE switching
Immunoglobulins	Low IgG, IgA, IgE; HIGH IgM	High IgE; other Ig variable
Infections	Opportunistic (PJP, Cryptosporidium) + pyogenic bacteria	Staph, Candida, Aspergillus
Neutropenia	Common (from impaired granulopoiesis)	Absent

Why high IgM? → B-cells can produce IgM (the default "first-line" antibody) without class-switch recombination. But switching from IgM to IgG/IgA/IgE requires CD40L-CD40 interaction between T-helper cells and B-cells. Without functional CD40L, class switching is blocked → IgM accumulates, IgG/IgA/IgE remain low.

3.2 Other Causes of Markedly Elevated IgE + Eczema in Children

This is probably the most common misdiagnosis in young children with STAT3-HIES, because the early eczematoid rash and elevated IgE overlap significantly.

Feature	Severe Atopic Dermatitis	STAT3-HIES
IgE	Elevated (typically 200–2000 IU/mL, rarely > 10,000)	Often > 2000 IU/mL, can exceed 50,000
Distribution	Flexural (antecubital, popliteal fossae) in older children; cheeks/extensor in infants ^[7]^[8]	Face, scalp, trunk; less classically flexural
Infections	Staph aureus superinfection common but episodic	Recurrent "cold" Staph abscesses — deeper, more frequent
Pneumatoceles	Absent	Present
Skeletal/dental features	Absent	Present
Facies	Dennie-Morgan folds, allergic shiners, central facial pallor ^[7]	Coarse facies: prominent forehead, broad nose, deep-set eyes
Allergic comorbidities	Asthma, allergic rhinitis (atopic triad)	Paradoxically LESS allergy/anaphylaxis than expected for IgE level
Family history	Strong atopic family history	Family history of HIES features or de novo

Key distinguishing point from lecture slides: "HIES has less allergy/anaphylaxis than expected for the IgE level" ^[6]. This is because the IgE in STAT3-HIES is polyclonal and non-specific, whereas in atopic disease it is directed against specific environmental allergens.

From Dermatology lecture slides ^[8]^[9]: The differential diagnosis of eczema includes "genetic or metabolic disorders featuring atopic eczema with or without raised IgE level, e.g. ataxia-telangiectasia, Wiskott-Aldrich syndrome" — and STAT3-HIES should be in this list.

A form of SCID with residual, dysregulated T-cell activity → oligoclonal T-cell expansion
Presents with: generalised erythroderma, eosinophilia, elevated IgE, lymphadenopathy, hepatosplenomegaly
Can mimic STAT3-HIES in infancy
Key distinguishing features: Very early onset (first weeks), failure to thrive, lymphadenopathy, hepatosplenomegaly, erythroderma (not discrete eczema), and usually low IgG/IgA/IgM despite high IgE

FOXP3 mutation → loss of regulatory T-cells
Presents with: severe eczema, high IgE, eosinophilia, autoimmune enteropathy (watery diarrhoea), type 1 diabetes (neonatal onset), autoimmune thyroiditis
Distinguished by prominent autoimmune features and X-linked inheritance

3.3 Non-Immunological Differentials (Based on Syndromic Features)

If the child presents primarily with skeletal or connective tissue features rather than infections:

Joint hypermobility, skin hyperextensibility, easy bruising
Distinguished by: No immunodeficiency, no elevated IgE, no recurrent infections, no pneumatoceles

Connective tissue disorder with vascular involvement (aneurysms, tortuosity) + skeletal features
Distinguished by: TGF-β receptor mutations; no immunodeficiency, no elevated IgE

Feature	STAT3-HIES	DOCK8 def.	WAS	CGD	LAD	SCID	Atopic eczema
Inheritance	AD	AR	XLR	XLR/AR	AR	XLR/AR	Polygenic
IgE	↑↑↑	↑↑↑	↑	Normal	Normal	Low	↑–↑↑
Eosinophils	↑	↑	Variable	Normal	Normal	Low	↑
Lymphocytes	Normal	Low (T)	Low (T)	Normal	Normal	↓↓↓	Normal
Platelets	Normal	Normal	↓ + small	Normal	Normal	Normal	Normal
Neutrophils	Normal	Normal	Normal	Normal	↑↑↑	Normal	Normal
Cold abscesses	Yes	No	No	No (hot)	No	N/A	No
Pneumatoceles	Yes	No	No	May have	No	No	No
Viral infections	No	Yes	Variable	No	Variable	Yes	No
Skeletal/dental	Yes	No	No	No	No	No	No
Coarse facies	Yes	No	No	No	No	No	No
Granulomas	No	No	No	Yes	No	No	No

From the Investigations of Immunological Disorders 2025 lecture ^[3]:

Approach to diagnosis of PID: Clinical history → Physical examination → Phenotypic investigations (IgG, IgA, IgM levels; vaccine responses; T, B, NK cell enumerations; lymphocyte subsets; cell function tests) → Genetic testing

The clinical approach in a child with suspected STAT3-HIES:

History: Age of onset of rash and infections; nature of infections (bacterial vs viral vs fungal); "cold" vs "hot" abscesses; retained teeth; fracture history; family history
Examination: Facies (coarse?), skin (eczema, scars, active abscesses), mouth (retained teeth, thrush), musculoskeletal (scoliosis, joint laxity)
First-line labs:
- CBC with differential → eosinophilia? thrombocytopenia (WAS)? lymphopenia (SCID)? neutrophilia (LAD)?
- Serum IgE level → markedly elevated (STAT3-HIES, DOCK8) vs normal (CGD, LAD)
- Immunoglobulins (IgG, IgA, IgM) → low IgG/IgA with high IgM (HIGM); panhypogammaglobulinaemia (XLA, SCID)
Second-line labs:
- T-cell subsets including Th17 quantification → low Th17 = STAT3-HIES
- DHR (dihydrorhodamine) flow cytometry → abnormal in CGD
- CD18 expression → absent in LAD
Genetic testing → definitive diagnosis ^[3]

When to Suspect STAT3-HIES Over Simple Eczema

If a child with "eczema" also has:

"Cold" abscesses (disproportionately non-tender)
Pneumatoceles on CXR
Any skeletal/dental/facial features
IgE > 2000 IU/mL
LESS allergic symptoms than expected (no food allergy, no anaphylaxis despite sky-high IgE)

→ Think STAT3-HIES and request Th17 quantification + STAT3 genetic testing.

Exam Pitfall: CGD vs HIES

Both CGD and STAT3-HIES present with recurrent Staphylococcus aureus infections. The critical distinguishing features are:

CGD: "Hot" abscesses with granuloma formation, enlarged BCG scar/BCG dissemination ^[5], hepatosplenomegaly, normal IgE, abnormal DHR
STAT3-HIES: "Cold" abscesses, pneumatoceles, coarse facies, retained teeth, markedly elevated IgE, low Th17

In the AOS past paper ^[5], the CGD case had: recurrent lymphadenitis with Staph aureus, enlarged BCG scar (2 cm), perianal sepsis, hepatosplenomegaly, normal CBC, elevated IgG → CGD, NOT HIES.

High Yield Summary — Differential Diagnosis of STAT3-HIES

DOCK8 deficiency (AR-HIES): The #1 differential. Distinguished by severe viral infections (molluscum, HPV, HSV), food allergy, NO pneumatoceles, NO skeletal features. HSCT is curative.
Wiskott-Aldrich syndrome: Eczema + micro-thrombocytopenia (small platelets) + immunodeficiency ± bloody diarrhoea. X-linked.
Chronic granulomatous disease: "Hot" abscesses, granulomas, BCG dissemination, hepatosplenomegaly, normal IgE. Phagocyte NADPH oxidase defect.
Leukocyte adhesion deficiency: Markedly elevated neutrophils, delayed cord separation, omphalitis, absent pus. CD18 defect.
SCID: Severe, early-onset, all infections, profound lymphopenia, absent thymic shadow, low all immunoglobulins.
Severe atopic eczema: Most common misdiagnosis. Distinguished by: flexural distribution, atopic triad, allergic comorbidities, NO pneumatoceles, NO skeletal features, less dramatically elevated IgE.
Hyper-IgM syndrome: High IgM, low IgG/IgA/IgE (opposite pattern to HIES).
NIH HIES score ≥ 40 + low Th17 cells + STAT3 mutation = definitive diagnosis.

Active Recall - Differential Diagnosis of STAT3-HIES

References

^[1] Lecture slides: GC 144. A child with recurrent infections Primary immunodeficiencies.pdf; Block C - A child with recurrent infections_ Primary immunodeficiencies.pdf ^[2] Senior notes: Jerry's immunodeficiencies.pdf (Block A and Block C sections) ^[3] Lecture slides: Investigations of Imm Disorders 2025.pdf (p10) ^[4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p638) ^[5] AOS material: AOS - Paeds.pdf (Q9) ^[6] Senior notes: Adrian Lui Pediatrics Notes.pdf (p411) ^[7] Senior notes: Block A - Dermatology PBL 1.pdf (p7) ^[8] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1787) ^[9] Lecture slides: Dermatology I Basics of Dermatology.pdf (p21)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for STAT3 Hyper-IgE Syndrome

1. Diagnostic Criteria

Unlike many conditions in medicine, there is no single universally accepted set of "diagnostic criteria" for STAT3-HIES in the way that, say, the Jones criteria define rheumatic fever or the Hanifin-Rajka criteria define atopic dermatitis. Instead, diagnosis relies on a stepwise approach:

Clinical suspicion (pattern recognition of the multi-system phenotype)
Clinical scoring (NIH HIES scoring system — screening tool)
Immunological phenotyping (Th17 quantification, IgE, eosinophils)
Genetic confirmation (STAT3 mutation — the gold standard)

From the GC 144 lecture slides ^[1]: "Many IEIs require tailored investigations, and cannot be picked up by initial screening tests. Always consult immunology when clinically suspicious." This is a critical principle — basic screening tests (CBC, immunoglobulins) will raise suspicion, but the definitive diagnosis of STAT3-HIES requires specialised flow cytometry and genetic testing.

This is the most widely used clinical screening tool to quantify the pre-test probability of STAT3-HIES before committing to genetic testing. It was developed at the National Institutes of Health (NIH) and assigns weighted points based on clinical and laboratory features.

Feature	Score Range	Notes
Highest serum IgE (IU/mL)	0–10	> 2000 = 10 pts; 1000–2000 = 8 pts; 500–1000 = 6 pts; 200–500 = 4 pts
Skin abscesses	0–8	≥ 4 episodes = 8 pts
Pneumonia episodes	0–8	≥ 3 episodes = 8 pts
Parenchymal lung abnormalities (pneumatoceles)	0–8	Present = 8 pts ^[1]^[2]
Retained primary teeth (≥ 3 beyond expected age)	0–8	Present = 8 pts
Scoliosis (maximal curvature in degrees)	0–6	> 20° = 6 pts
Fractures with minor trauma	0–4	≥ 2 fractures = 4 pts
Characteristic (coarse) facies	0–5	Present = 5 pts
Eczema (worst severity)	0–4	Severe/persistent = 4 pts
Upper respiratory infections per year	0–4	≥ 6 = 4 pts
Candidiasis (mucocutaneous)	0–4	Present = 4 pts
Other serious infections	0–4	Present = 4 pts
Newborn rash	0–4	Present = 4 pts
Hyperextensibility of joints	0–4	Present = 4 pts
Lymphoma	0–4	Present = 4 pts
High-arched palate	0–2	Present = 2 pts
Midline anomaly	0–2	Present = 2 pts
Young age correction	Variable	Lower threshold for younger children who haven't yet manifested later features

Interpretation:

NIH Score	Interpretation
≥ 40	Highly suggestive of STAT3-HIES → proceed to genetic testing
20–40	Possible STAT3-HIES → consider genetic testing, especially if Th17 cells low
< 20	Unlikely STAT3-HIES (but does not exclude it in very young infants)

Paediatric Caveat with the NIH Score

The NIH scoring system was developed largely in older children and adults. In infants and very young toddlers, many syndromic features (retained primary teeth, scoliosis, fractures, characteristic facies) have not yet had time to develop. A young infant may have STAT3-HIES with a score < 40 simply because they are too young to have accumulated points. In such cases, a strong clinical suspicion (neonatal eczematoid rash + cold abscesses + elevated IgE) plus low Th17 cells should trigger genetic testing even with a low NIH score.

In current practice, the diagnosis of STAT3-HIES is established when all three of the following are met:

Compatible clinical phenotype: ≥ 2 of the following:
- Recurrent "cold" staphylococcal abscesses
- Recurrent pneumonia (especially with pneumatocele formation)
- Eczematoid dermatitis from infancy
- Characteristic coarse facies
- Retained primary teeth / skeletal abnormalities
- Chronic mucocutaneous candidiasis
Supportive laboratory findings:
- Markedly elevated serum IgE (typically > 2000 IU/mL) ^[1]^[2]
- Elevated absolute eosinophil count ^[2]
- Low/absent Th17 cells on flow cytometry
- NIH HIES score ≥ 40 (supportive but not required)
Confirmatory genetic testing: Pathogenic or likely pathogenic heterozygous variant in the STAT3 gene ^[3]

From the Investigations of Immunological Disorders 2025 lecture ^[3]: "Genetic testing has an important role in: Diagnosis (All cases), Family studies, Prognostication, Prenatal diagnosis, Defining new diseases." Genetic testing is considered essential for definitive diagnosis of all primary immunodeficiencies, including STAT3-HIES.

The algorithm follows the general approach to diagnosis of PID outlined in the GC and medicine lectures ^[1]^[3]:

Clinical history → Physical examination → Phenotypic investigations (IgG, IgA, IgM levels; vaccine responses; T, B, NK cell enumerations; lymphocyte subsets; cell function) → Genetic testing ^[3]

3. Investigation Modalities — Detailed Breakdown

The investigations are presented in the order you would typically request them, from bedside/first-line to specialised/genetic.

3.1 First-Line Investigations (Available in Any Paediatric Unit)

This is the single most important first-line screening test for any suspected PID ^[1].

Parameter	Expected Finding in STAT3-HIES	Interpretation	What It Rules Out
WBC	Normal or mildly elevated	Unlike SCID (low) or LAD (high neutrophils)
Absolute lymphocyte count (ALC)	Normal (≥ 2500/µL in infants, ≥ 1500/µL in > 5 years) ^[4]	T-cell development is intact (the defect is in Th17 differentiation, not total T-cell numbers)	ALC < 3000 in < 1 year or < 1000 in > 1 year → think SCID ^[1]
Absolute eosinophil count (AEC)	Elevated (eosinophilia) ^[1]^[2]	Reflects Th2 skewing and dysregulated IgE switching	AEC high → supports HIES or primary atopic disorder ^[1]
Platelet count	Normal	Rules out WAS	PLT low → think Wiskott-Aldrich syndrome ^[1]; also check MPV (small platelets in WAS)
Absolute neutrophil count (ANC)	Normal	Rules out LAD (high ANC) and severe congenital neutropenia (low ANC)	ANC high → think LAD; ANC < 1 → severe congenital neutropenia ^[1]
Haemoglobin	Usually normal	Anaemia may suggest chronic disease

GC High Yield — CBC Findings in PIDs

From GC 144 lecture ^[1]:

ALC low < 3000 (< 1y) or < 1000 (> 1y) → severe combined immunodeficiencies
AEC high → primary atopic disorders
ANC < 1 → severe congenital neutropenia
ANC high → leukocyte adhesion deficiency
AMC low → GATA2 deficiency
PLT low → Wiskott-Aldrich syndrome

These are one-liner associations that are extremely high yield for the written paper.

From GC 144 lecture ^[1]: "IgGAME" — check IgG, IgA, IgM, and IgE together.

Immunoglobulin	Expected in STAT3-HIES	Interpretation
IgE	Markedly elevated, typically > 2000 IU/mL, often > 10,000 IU/mL ^[1]^[2]	Reflects dysregulated B-cell class switching due to impaired IL-21/IL-10 → STAT3 signalling; IgE is polyclonal, non-specific
IgG	Normal or low-normal	May be mildly reduced; some patients have impaired specific antibody production despite normal total IgG
IgA	Normal or variable
IgM	Normal	Helps exclude hyper-IgM syndrome (high IgM) and WAS (low IgM)

From GC 144 lecture ^[1]:

High IgE → hyper-IgE syndrome, primary atopic disorder

High IgM → hyper-IgM syndrome

High IgGAM → chronic granulomatous disease

Low IgGAM → agammaglobulinaemia (e.g. XLA)

Low IgM → DOCK8 deficiency, Wiskott-Aldrich syndrome, ataxia-telangiectasia

Paediatric age-related reference ranges for IgE:

IgE levels must be interpreted against age-specific reference ranges (IgE rises throughout childhood and plateaus in adolescence)
In STAT3-HIES, the IgE is so dramatically elevated that it exceeds normal ranges by 10–100×, making interpretation straightforward in most cases
Caveat: IgE may be lower (still elevated but < 2000 IU/mL) in infants or during disease remission — a single "normal" IgE does not exclude STAT3-HIES if clinical features are present

IgE > 2000 but Not Always

While most STAT3-HIES patients have IgE > 2000 IU/mL at some point, IgE levels fluctuate and may decline with age (some adults with confirmed STAT3 mutations have IgE in the hundreds). Always use the highest ever recorded IgE for the NIH scoring system. In paediatrics, the initial IgE in an infant may not yet have reached peak levels — serial measurements are important.

Finding	Interpretation	Pathophysiological Basis
Pneumatoceles	Hallmark radiographic finding of STAT3-HIES ^[1]^[2] — persistent air-filled cystic cavities in lung parenchyma	Post-infectious parenchymal destruction + impaired tissue repair (STAT3 → MMP dysregulation → failure to repair lung after pneumonia)
Consolidation	Active pneumonia	Suggests current bacterial infection
Air-fluid levels within cysts	Superinfection of pre-existing pneumatoceles	Pseudomonas, NTM, or Aspergillus colonising/infecting the cysts
Bronchiectasis	Chronic airway damage from recurrent infections
Thymic shadow	Present (normal)	Helps exclude SCID (absent thymic shadow)

From GC 144 lecture ^[1]: Radiographic findings of patients with AD STAT3 hyper-IgE syndrome are shown — the classic image shows massive pneumatoceles ^[2].

"CXR showing massive pneumatoceles" is listed as a key test finding for HIES in the lecture notes ^[2].

Marker	Expected in STAT3-HIES	Interpretation
CRP	Often fails to rise appropriately during acute infection	IL-6 → STAT3 → CRP gene transcription is impaired; this is why infections appear deceptively mild ("cold")
ESR	Variable; may be mildly elevated	Less dependent on STAT3 pathway

Why does CRP fail to rise?

CRP is an acute phase protein synthesised by hepatocytes in response to IL-6
IL-6 signals through the JAK-STAT3 pathway to activate CRP gene transcription
In STAT3-HIES, this pathway is impaired → CRP production is blunted even during serious infection
This is clinically dangerous because clinicians may be falsely reassured by a "normal" CRP in a child who is actually severely infected

Clinical Pearl

In a child with known STAT3-HIES, never rely on CRP to gauge infection severity. The CRP may be inappropriately low. Use clinical assessment, imaging, and microbiological cultures to guide management.

Specimen	Purpose	Expected Organisms
Wound/abscess swab	Identify causative organism of skin abscess	S. aureus (most common); may be MRSA or MSSA
Blood culture	Exclude bacteraemia/sepsis during febrile episodes	S. aureus, Streptococcus, Gram-negatives
Sputum/BAL culture	Identify pulmonary pathogens	S. aureus, H. influenzae, S. pneumoniae; Pseudomonas and Aspergillus in pneumatoceles
Fungal culture	Candida, Aspergillus	Oral/skin swabs, BAL
Galactomannan/β-D-glucan	Screen for invasive aspergillosis	Elevated in invasive fungal infection

3.2 Second-Line Investigations (Immunology Laboratory)

These are requested when first-line findings raise suspicion for STAT3-HIES (elevated IgE, eosinophilia, pneumatoceles, clinical phenotype).

From GC 144 lecture ^[1] and Investigations of Imm Disorders 2025 ^[3]: Lymphocyte subset enumeration is a key phenotypic investigation.

Subset	Expected in STAT3-HIES	Interpretation
Total T cells (CD3+)	Normal	T-cell development is intact; distinguishes from SCID
CD4+ T cells	Normal total, but naïve CD4+ (CD45RA+) may be reduced
CD8+ T cells	Normal
Th17 cells (CD4+IL-17A+)	Markedly reduced or absent	This is the hallmark immunological finding — IL-6/IL-23 → STAT3 → RORγt pathway is required for Th17 differentiation; STAT3 LOF blocks this
B cells (CD19+ or CD20+)	Normal total
Memory B cells (CD27+IgD−, class-switched)	Reduced	IL-21 → STAT3 required for germinal centre reactions and memory B-cell generation
NK cells (CD16+CD56+)	Normal

From GC 144 lecture ^[1]:

Low T cells (with or without low B and/or NK) → combined immunodeficiencies

Low B cells only → agammaglobulinaemia

"In some forms of CID, T cell may be normal in count but not in function, or they may be maternally grafted memory T cells in Omenn syndrome, a form of SCID"

In STAT3-HIES, total T-cell counts are normal — the defect is qualitative (impaired Th17 differentiation), not quantitative. This is why standard lymphocyte subset panels may appear normal and you must specifically request Th17 quantification (intracellular IL-17A staining after stimulation).

This is the most informative immunological test for STAT3-HIES:

Method: PBMCs are stimulated in vitro (e.g., with PMA + ionomycin or anti-CD3/CD28), then stained intracellularly for IL-17A. The percentage of CD4+ T cells producing IL-17A is quantified by flow cytometry.
Normal: Th17 cells constitute ~1–3% of CD4+ T cells (varies by age and laboratory)
In STAT3-HIES: Th17 cells are markedly reduced (often < 0.5% or undetectable)
Sensitivity: Very high for STAT3-HIES; virtually all patients with confirmed STAT3 mutations have low Th17 cells
Specificity: Not 100% — DOCK8 deficiency and some other PIDs may also have reduced Th17 cells, so genetic testing is still needed for confirmation

From the Investigations of Imm Disorders 2025 lecture ^[3]: "Vaccine responses" are listed as a key phenotypic investigation.

Vaccine	What to Measure	Expected in STAT3-HIES
Pneumococcal polysaccharide	Anti-pneumococcal IgG (serotype-specific)	May be impaired — poor response to polysaccharide antigens
Tetanus/Diphtheria	Anti-tetanus, anti-diphtheria IgG	Often normal (protein-conjugate vaccines → T-dependent response may be partially preserved)
Hepatitis B	Anti-HBs	Variable

Why are vaccine responses impaired?

IL-21 → STAT3 is required for germinal centre B-cell reactions and formation of long-lived plasma cells/memory B cells
Without adequate STAT3 signalling, the germinal centre reaction is suboptimal → poor affinity maturation and memory B-cell formation → inadequate long-term antibody responses
This is clinically important: some STAT3-HIES patients may benefit from IVIG supplementation if specific antibody deficiency is demonstrated ^[2]

Purpose: Exclude chronic granulomatous disease (CGD)
DHR assay uses flow cytometry to measure neutrophil oxidative burst (NADPH oxidase activity)
In STAT3-HIES: DHR is NORMAL (phagocyte oxidative burst is intact; the defect is in Th17 cells, not in neutrophil killing)
In CGD: DHR is ABNORMAL (neutrophils cannot produce ROS)

This test is important because both CGD and STAT3-HIES present with recurrent Staph aureus infections, and distinguishing them is critical ^[5].

3.3 Definitive Investigation: Genetic Testing

From the Investigations of Imm Disorders 2025 lecture ^[3]: "Genetic testing has an important role in: Diagnosis (All cases), Family studies, Prognostication, Prenatal diagnosis"

Modality	Detail
Target	STAT3 gene, chromosome 17q21.2
Method	Sanger sequencing of STAT3 exons (targeted) OR next-generation sequencing (NGS) PID gene panel OR whole-exome sequencing (WES)
Expected finding	Heterozygous pathogenic or likely pathogenic variant (missense, in-frame deletion) — typically in the SH2 domain or DNA-binding domain
Variant type	Loss-of-function, dominant-negative — the mutant protein poisons wild-type STAT3 function by forming non-functional heterodimers
Interpretation	A pathogenic STAT3 variant in a patient with compatible phenotype = confirmed diagnosis

Hotspot mutation domains:

SH2 domain (most common) — R382W, V637M are recurrent variants
DNA-binding domain — also frequently affected
Transactivation domain, coiled-coil domain — less common

When genetic testing is inconclusive:

If no STAT3 variant is found but clinical suspicion is high → consider:
- Whole-exome or whole-genome sequencing
- Testing for other HIES genes: DOCK8, ZNF341, IL6ST, IL6R, PGM3, ERBIN
- Somatic mosaicism (variant present in a fraction of cells, may be missed by standard sequencing)
- Variants of uncertain significance (VUS) — may require functional studies

A research/specialist test where patient cells (PBMCs or fibroblasts) are stimulated with IL-6 or IL-10, and the degree of STAT3 phosphorylation (Tyr705) is measured by flow cytometry or western blot
In STAT3-HIES: STAT3 phosphorylation is reduced (dominant-negative effect)
Useful when a VUS is found and functional significance needs to be confirmed

These are not diagnostic per se but are important for baseline assessment and ongoing surveillance once the diagnosis is established:

Investigation	Purpose	Expected Findings
CT Thorax	Detailed assessment of pneumatoceles, bronchiectasis	Better defines extent of lung parenchymal disease than CXR
DEXA scan / Bone densitometry	Assess bone mineral density	Reduced BMD (osteopenia/osteoporosis); guides fracture prevention
Spinal X-ray	Assess scoliosis	Lateral curvature; Cobb angle measurement
Panoramic dental X-ray	Assess retained primary teeth, unerupted permanent teeth	Retained deciduous tooth roots not resorbed; double rows
Echocardiography	Screen for coronary artery abnormalities	Coronary artery dilatation or aneurysms (especially in adolescents)
MRA brain	Screen for cerebral aneurysms	Berry aneurysms (especially in adolescents/young adults)
Pulmonary function tests	Baseline lung function and monitoring	May show restrictive or obstructive patterns depending on extent of pneumatoceles/bronchiectasis
Serum IgE serial monitoring	Track IgE trend	IgE may decline with age; does not necessarily correlate with disease activity

Stage	Investigations	Key Findings
First-line	CBC with D/C, IgG/IgA/IgM/IgE, CXR, CRP, Cultures	Eosinophilia, IgE > 2000, pneumatoceles, inappropriately low CRP, Staph/Candida on culture
Clinical scoring	NIH HIES score	≥ 40 highly suggestive
Second-line	Th17 quantification, lymphocyte subsets, specific Ab responses, DHR assay	Low/absent Th17 cells, reduced memory B cells, normal DHR
Definitive	STAT3 genetic testing ^[3]	Heterozygous pathogenic STAT3 variant
Adjunctive	CT thorax, DEXA, spinal XR, dental XR, echo, MRA brain	Pneumatoceles, osteopenia, scoliosis, retained teeth, aneurysms

High Yield Summary — Diagnosis of STAT3-HIES

No single diagnostic criterion — use clinical phenotype + NIH score + Th17 quantification + genetic confirmation
First-line CBC findings for PIDs (GC high yield): Low ALC → SCID; High AEC → HIES/atopic; Low PLT → WAS; High ANC → LAD; High IgE → HIES
IgE typically > 2000 IU/mL but may fluctuate; use highest ever recorded value
Th17 quantification by intracellular IL-17A staining is the most informative immunological test
CXR pneumatoceles are the hallmark radiographic finding
CRP may be inappropriately low during active infection (impaired IL-6 → STAT3 → CRP pathway)
Genetic testing (STAT3 sequencing) is the gold standard for definitive diagnosis
DHR assay should be normal in STAT3-HIES — order it to exclude CGD in children with recurrent Staph infections
NIH score ≥ 40 = highly suggestive; but in young infants, score may be low due to incomplete phenotype development → still test if suspicious
Always consult immunology when clinically suspicious — many IEIs cannot be picked up by initial screening tests

Active Recall - Diagnostic Criteria and Investigations of STAT3-HIES

References

^[1] Lecture slides: GC 144. A child with recurrent infections Primary immunodeficiencies.pdf (p25, p50) ^[2] Senior notes: Jerry's immunodeficiencies.pdf (Block A and Block C sections) ^[3] Lecture slides: Investigations of Imm Disorders 2025.pdf (p10, p16) ^[4] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf (p638) ^[5] AOS material: AOS - Paeds.pdf (Q9)

Management of STAT3 Hyper-IgE Syndrome

STAT3-HIES is a lifelong, multisystem genetic disorder with no current cure for most patients. Unlike DOCK8 deficiency (where HSCT is curative and recommended), the role of HSCT in STAT3-HIES remains uncertain because:

The non-immunological features (skeletal, dental, vascular, connective tissue) are driven by STAT3 deficiency in non-haematopoietic tissues — replacing the immune system via HSCT does not fix these
HSCT outcomes in STAT3-HIES have been variable, with significant transplant-related morbidity

Therefore, management is built on four pillars:

Antimicrobial prophylaxis — prevent the infections that cause morbidity and mortality
Aggressive treatment of acute infections — early and targeted
Immunoglobulin replacement — compensate for impaired specific antibody production
Multisystem surveillance and supportive care — skin, skeleton, dentition, vasculature, lungs

From the lecture notes ^[2]: Treatment of STAT3-HIES = "Septrin + IVIG + secukinumab" — this is the concise high-yield triad to remember for exams.

3. Treatment Modalities — Detailed Breakdown

3.1 Antimicrobial Prophylaxis

This is the cornerstone of management. The goal is to prevent the recurrent bacterial and fungal infections that drive morbidity (pneumatoceles, bronchiectasis, organ damage) and mortality.

Parameter	Detail
Drug	Trimethoprim-sulfamethoxazole (Septrin) ^[2]
Rationale	Excellent anti-staphylococcal activity (covers both MSSA and community-acquired MRSA); also provides prophylaxis against Pneumocystis jirovecii (PJP) — a relevant opportunistic pathogen in T-cell deficiencies
Mechanism	Sequential blockade of folate synthesis: sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase → bacteria cannot synthesise tetrahydrofolate → cannot make purines/thymidine → bacteriostatic/bactericidal
Paediatric dosing	TMP 5 mg/kg/day (max 320 mg/day) in 1–2 divided doses, daily or 3 days per week
Formulation	Oral suspension (paediatric formulation: TMP 40 mg + SMX 200 mg per 5 mL); tablets for older children
Duration	Lifelong
Monitoring	FBC (rare: neutropenia, megaloblastic anaemia from folate antagonism), renal function, LFTs
Side effects	Rash, GI upset, bone marrow suppression (rare), Stevens-Johnson syndrome (very rare), hyperkalaemia
Contraindications	Sulfonamide allergy (true Type I hypersensitivity); severe hepatic/renal impairment; G6PD deficiency (relative — can cause haemolysis)

Why TMP-SMX specifically?

It covers S. aureus (the #1 pathogen in STAT3-HIES) with good tissue penetration, including skin and lung
It simultaneously covers PJP, which is relevant given the T-cell (Th17) deficiency
It is cheap, well-tolerated, and available in paediatric liquid formulation
It has been the standard prophylactic antibiotic for STAT3-HIES for decades

If Sulfonamide-Allergic

In children who cannot tolerate TMP-SMX, alternatives for anti-staphylococcal prophylaxis include:

Dicloxacillin or flucloxacillin (anti-staphylococcal penicillins)
Clindamycin (good skin/soft tissue penetration; also covers MRSA)
PJP prophylaxis must then be covered separately with dapsone or atovaquone

Parameter	Detail
Drug	Itraconazole (first-line) or Fluconazole
Rationale	Patients are susceptible to Candida (mucocutaneous) and Aspergillus (invasive, especially in pneumatoceles) due to Th17 deficiency → IL-17/IL-22 impaired → epithelial antifungal defence compromised
Itraconazole	Broader spectrum than fluconazole; covers Aspergillus (which fluconazole does NOT)
Paediatric dosing (itraconazole)	5 mg/kg/day oral solution (better bioavailability than capsules in children); take on empty stomach for solution form
Fluconazole	3–6 mg/kg/day; adequate for Candida prophylaxis but does NOT cover Aspergillus
Duration	Lifelong (or at minimum when pneumatoceles are present, which is an ongoing Aspergillus colonisation risk)
Monitoring	LFTs (azole hepatotoxicity), drug levels (itraconazole trough > 0.5 mg/L for efficacy)
Side effects	Hepatotoxicity, GI upset, drug interactions (CYP3A4 inhibitor — interacts with many drugs)
Contraindications	Severe hepatic impairment; concurrent use of drugs with major CYP3A4 interactions (e.g. certain statins, some immunosuppressants)

Why itraconazole over fluconazole?

Fluconazole is effective against Candida but has no activity against Aspergillus (Aspergillus species are intrinsically resistant to fluconazole)
Itraconazole covers both Candida AND Aspergillus → more appropriate in STAT3-HIES where pneumatoceles create a nidus for Aspergillus colonisation/infection
Some centres use fluconazole in younger children without pneumatoceles and escalate to itraconazole once lung disease develops

3.2.1 Intravenous Immunoglobulin (IVIG) [2]

Parameter	Detail
Indication	Demonstrated specific antibody deficiency (poor vaccine responses) and/or recurrent sinopulmonary infections despite antimicrobial prophylaxis ^[2]
Rationale	Although total IgG may be normal in STAT3-HIES, specific antibody responses are often impaired (due to defective IL-21 → STAT3 germinal centre signalling → poor memory B-cell and long-lived plasma cell generation). IVIG provides a broad repertoire of pre-formed IgG antibodies that compensate for this defect
Paediatric dosing	400–600 mg/kg IV every 3–4 weeks
Target trough IgG	Typically > 8 g/L (some centres aim higher, > 10 g/L, in patients with bronchiectasis)
Administration	IV infusion over 2–4 hours; pre-medication with paracetamol ± antihistamine to reduce infusion reactions
Side effects	Infusion reactions (headache, fever, chills, myalgia), anaphylaxis (rare, especially in IgA-deficient patients with anti-IgA antibodies), aseptic meningitis, thromboembolic events, haemolytic anaemia
Contraindications	Complete IgA deficiency with anti-IgA antibodies (rare; use IgA-depleted product); known hypersensitivity to immunoglobulin products

Alternative: Subcutaneous Immunoglobulin (SCIG)

Same total monthly dose divided into weekly subcutaneous injections
Advantages: can be administered at home by trained caregivers (family-centred care), avoids IV access, more stable serum IgG levels (no "peak-trough" fluctuation)
Disadvantage: requires training, multiple injection sites, local site reactions
Increasingly preferred for paediatric patients for quality-of-life reasons

When to Start IVIG in STAT3-HIES

Not all STAT3-HIES patients need IVIG. The decision is based on:

Documented poor vaccine responses (e.g. inadequate anti-pneumococcal IgG after vaccination)
Recurrent bacterial infections despite adequate TMP-SMX prophylaxis
Bronchiectasis or progressive lung disease

If a patient has adequate specific antibody responses and infections are well controlled with Septrin alone, IVIG may be deferred with close monitoring.

The eczematoid dermatitis in STAT3-HIES is chronic and often the earliest manifestation. Management parallels atopic eczema management but with some important differences.

Intervention	Detail	Paediatric Considerations
Emollients	Regular, liberal application of fragrance-free moisturisers (e.g. aqueous cream, cetaphil, emulsifying ointment) at least 2–3 times daily	Apply within 3 minutes of bathing ("soak and seal"); paediatric formulations widely available
Topical corticosteroids	For flares: mild (hydrocortisone 1%) for face/flexures; moderate (betamethasone valerate 0.025%) for body; use short courses	Avoid prolonged use of potent steroids in children (skin atrophy, adrenal suppression); step-down approach
Topical calcineurin inhibitors	Tacrolimus ointment 0.03% (for children ≥ 2 years) or pimecrolimus cream — steroid-sparing for sensitive areas (face, eyelids, groin)	Off-label in children < 2 years; monitor for local burning sensation
Antiseptic baths/washes	Dilute bleach baths (sodium hypochlorite 0.005%) 2–3 times per week to reduce S. aureus skin colonisation	Evidence-based for reducing Staph colonisation and eczema flares
Topical antibiotics	Mupirocin 2% ointment for localised impetiginised eczema or nasal decolonisation of Staph	Avoid prolonged use (resistance); limited course (5–7 days)

Why bleach baths?

STAT3-HIES patients have heavy S. aureus colonisation of the skin (because Th17/IL-22 deficiency impairs cutaneous antimicrobial peptide production)
Dilute bleach baths reduce the bacterial load on skin surfaces, reducing the frequency of secondary infection and eczema flares
This is an inexpensive, evidence-based intervention applicable to all children with Staph-colonised eczema

3.4 Targeted Biologic Therapies

These represent newer, precision-medicine approaches being increasingly used in STAT3-HIES.

Parameter	Detail
Drug class	Fully human IgG1κ monoclonal antibody targeting IL-17A
Rationale	In STAT3-HIES, Th17 cells are deficient → IL-17A production is severely reduced. However, some residual IL-17A may be produced by other cell types (γδ T cells, ILC3s). Paradoxically, anti-IL-17A therapy is listed in the lecture notes ^[2] and has been reported to improve certain features. The mechanism is debated — it may work by modulating dysregulated inflammatory pathways or reducing eosinophilic inflammation rather than simply supplementing the Th17 defect
Evidence	Case reports and small series showing improvement in skin disease and reduction in some infections; not yet supported by large clinical trials
Dosing (paediatric)	Based on weight; typically 150 mg SC in children < 50 kg; loading doses at weeks 0, 1, 2, 3, 4, then monthly
Monitoring	Monitor for new or worsening infections (especially candidiasis, since anti-IL-17A further impairs Candida defence); inflammatory markers
Side effects	Mucocutaneous candidiasis (already a problem in STAT3-HIES), nasopharyngitis, injection site reactions
Contraindications	Active severe infection; hypersensitivity to secukinumab

Exam Note on Secukinumab

The use of secukinumab in STAT3-HIES is mentioned in the lecture notes ^[2] and is therefore examinable, but be aware that this is an evolving area. The evidence base is limited to case series. The theoretical concern is that blocking IL-17A in a patient who already has Th17 deficiency could worsen fungal susceptibility. In practice, it has been used cautiously with concurrent antifungal prophylaxis. For exam purposes, simply know that "Septrin + IVIG + secukinumab" is the treatment triad taught in the HKU lectures ^[2].

Parameter	Detail
Drug class	Fully human IgG4 monoclonal antibody targeting the α-subunit of the IL-4 receptor (shared by IL-4 and IL-13 signalling)
Rationale	Blocks IL-4 and IL-13 → key Th2 cytokines driving eczema, IgE production, and eosinophilia. By blocking the Th2 axis, dupilumab reduces IgE levels, improves eczema, and may partially correct the Th2/Th17 imbalance
Evidence	Multiple case reports and a growing series showing significant improvement in eczema severity, reduction in IgE levels, and reduced infection frequency in STAT3-HIES patients
Paediatric indication	Approved for moderate-to-severe atopic dermatitis in children ≥ 6 months; off-label for STAT3-HIES eczema
Dosing (paediatric)	Weight-based; e.g. 200 mg SC every 2 weeks for children 15–30 kg; 300 mg for > 60 kg
Monitoring	Eosinophil count (transient eosinophilia may occur initially), eye symptoms (conjunctivitis is a known side effect)
Side effects	Injection site reactions, conjunctivitis, transient eosinophilia
Contraindications	Hypersensitivity to dupilumab

Why is dupilumab potentially better than secukinumab for the eczema component?

The eczema in STAT3-HIES has a strong Th2-driven component (high IgE, eosinophilia)
Dupilumab directly targets the Th2 cytokine axis (IL-4/IL-13), which is the primary driver of eczematous skin inflammation
Case reports show dramatic improvement in eczema, reduction in IgE, and even reduction in infection frequency (possibly by restoring skin barrier function)
Dupilumab does NOT worsen anti-candidal immunity (unlike anti-IL-17A)

Infection Type	First-Line Treatment	Key Considerations
Skin/soft tissue abscess	Incision and drainage (I&D) + anti-staphylococcal antibiotics (IV flucloxacillin/cloxacillin if MSSA; IV vancomycin if MRSA)	Always send pus for culture and sensitivity; remember CRP may be misleadingly low
Pneumonia	IV anti-staphylococcal antibiotic (flucloxacillin/vancomycin) + broad-spectrum cover (e.g. ceftriaxone or amoxicillin-clavulanate); add atypical cover if indicated	Obtain blood cultures and sputum/BAL culture; CT thorax to assess for pneumatocele complications
Superinfected pneumatocele	Based on culture: Pseudomonas (piperacillin-tazobactam or meropenem + aminoglycoside), Aspergillus (voriconazole or amphotericin B), NTM (multi-drug regimen)	May require prolonged courses (weeks to months); surgical resection considered for refractory cases
Mucocutaneous candidiasis	Oral fluconazole (6 mg/kg loading, then 3 mg/kg/day); nystatin oral suspension for mild oral thrush	Escalate to itraconazole or voriconazole if azole-resistant Candida
Invasive aspergillosis	Voriconazole (first-line for invasive aspergillosis) or liposomal amphotericin B; add echinocandin (caspofungin/micafungin) for salvage	Therapeutic drug monitoring for voriconazole (trough 1–5.5 mg/L); hepatotoxicity, visual disturbances

Surgical Considerations for Pneumatoceles

Pneumatoceles are a major source of chronic morbidity in STAT3-HIES. Once formed, they do not resolve spontaneously and become colonised with Pseudomonas, NTM, and Aspergillus. Surgical resection (lobectomy or segmentectomy) is considered when:

Pneumatoceles are chronically infected despite prolonged antimicrobial therapy
Massive pneumatoceles cause respiratory compromise
Bronchopleural fistula develops

Surgery carries risks (poor wound healing in STAT3-HIES, post-operative infection), so the decision is made by a multidisciplinary team (paediatric immunology + respiratory + thoracic surgery).

Intervention	Detail	Rationale
Regular dental surveillance	6-monthly dental reviews from age 1 year	Early detection of retained primary teeth and dental caries
Elective extraction of retained primary teeth	Extract deciduous teeth that have not shed by expected age to allow permanent teeth to erupt in correct alignment	In STAT3-HIES, impaired IL-11 → STAT3 → osteoclast activation means primary tooth roots are not resorbed → teeth must be mechanically removed
Orthodontic assessment	Refer for orthodontic evaluation if malocclusion develops	Prevention of long-term dental complications
Antibiotic prophylaxis before dental procedures	Consider antibiotic cover (amoxicillin) before invasive dental procedures in immunocompromised patients	Prevent bacteraemia and secondary infection

Intervention	Detail	Rationale
Bone health optimisation	Adequate calcium and vitamin D intake; weight-bearing exercise as tolerated	Patients have reduced BMD → osteopenia/osteoporosis → fractures with minimal trauma
DEXA monitoring	Baseline DEXA and repeat every 1–2 years	Track BMD trend; guide intensity of osteoporosis prevention
Bisphosphonates	Consider in children with recurrent pathological fractures or significantly reduced BMD (pamidronate IV or oral alendronate)	Bisphosphonates inhibit osteoclast-mediated bone resorption → increase BMD; paediatric use guided by specialist
Scoliosis monitoring	Annual spinal examination + standing AP spine radiograph if curvature detected	Early detection allows bracing; severe scoliosis (Cobb > 40–50°) may require surgical correction
Fracture prevention	Avoid high-impact contact sports; occupational therapy assessment for adaptive strategies	Prevent pathological fractures in fragile bones

Screening	Method	Timing
Coronary arteries	Echocardiography	Baseline at diagnosis; repeat in adolescence
Cerebral vasculature	MRA brain	Baseline in adolescence; repeat every 3–5 years or if symptoms
Aortic root/ascending aorta	Echocardiography or CT angiography	Periodic screening

Why screen? STAT3 is involved in VEGF/EGF-mediated vascular smooth muscle maintenance. Loss of STAT3 signalling weakens vessel walls → aneurysm formation. Coronary and cerebral aneurysms may cause MI or subarachnoid haemorrhage — potentially fatal complications that are preventable if detected early.

Parameter	Detail
Current status	NOT standard of care for STAT3-HIES (unlike DOCK8 deficiency where HSCT is curative and recommended)
Rationale for caution	(1) Non-immunological features (skeletal, dental, vascular) are driven by STAT3 deficiency in non-haematopoietic tissues → HSCT cannot correct these; (2) Historical outcomes have shown variable success with significant transplant-related morbidity and mortality
Potential indication	Considered on a case-by-case basis for patients with severe, life-threatening infections refractory to all medical therapy, or those with severe pulmonary disease
Emerging data	Recent case series suggest that HSCT may improve the immunological phenotype (infections, eczema) even though skeletal/vascular features persist; outcomes are improving with better conditioning regimens
Conditioning	Typically reduced-intensity conditioning (RIC) to minimise toxicity
Donor	Matched sibling or unrelated donor; haploidentical with post-transplant cyclophosphamide increasingly used

HSCT: STAT3-HIES vs DOCK8 vs SCID

PID	HSCT Role
SCID	HSCT is the definitive treatment — perform as early as possible (ideally before 3.5 months)
DOCK8 deficiency	HSCT is curative and recommended — corrects the immunological defect and prevents malignancy
STAT3-HIES	HSCT is NOT standard; considered only for severe refractory cases — corrects immune defect but NOT skeletal/vascular features

Gene therapy and gene editing (e.g. CRISPR-Cas9 correction of the STAT3 mutation in haematopoietic stem cells) are under investigation as a potential curative approach
Still in preclinical/early clinical stages
The challenge of correcting a dominant-negative mutation is that you must either silence the mutant allele or correct it, not simply add a normal copy (gene addition alone may not overcome the dominant-negative effect)
Not yet clinically available (as of 2025–2026)

Aspect	Detail
Genetic counselling	Autosomal dominant → 50% recurrence risk if a parent is affected; de novo in ~60–70% (lower recurrence risk but gonadal mosaicism possible)
Family screening	Screen parents and siblings clinically and genetically once a STAT3 variant is identified → some family members may have milder phenotypes
Prenatal diagnosis	Available via chorionic villus sampling or amniocentesis if the familial variant is known
Psychological support	Chronic disease in childhood → impact on body image (coarse facies, scars from abscesses), school attendance, activity restrictions (fracture risk)
Transition planning	Plan transition from paediatric to adult immunology services in adolescence (typically 16–18 years in Hong Kong)
Education	Teach family about infection signs, when to seek medical attention, importance of adherence to prophylaxis, skin care routine
School liaison	Inform school about the child's condition, need for infection avoidance, medication administration during school hours

Vaccine Type	Recommendation	Rationale
Inactivated vaccines	Give all standard inactivated vaccines (DTaP, IPV, HepB, pneumococcal conjugate, meningococcal, influenza)	Safe in immunodeficient patients; may have suboptimal response → check antibody titres post-vaccination
Live vaccines	Generally AVOID live vaccines (BCG, MMR, varicella, oral polio, rotavirus, LAIV)	T-cell defect (albeit primarily Th17) → theoretical risk of disseminated vaccine-strain infection; however, practice varies — some centres allow MMR/varicella if T-cell counts are adequate
Pneumococcal conjugate + polysaccharide	Give PCV13 series; consider PPSV23 at age ≥ 2 years	Assess specific anti-pneumococcal antibody responses to determine if IVIG is needed
Influenza (inactivated)	Annual inactivated influenza vaccine	Safe; important given respiratory susceptibility
Household contacts	Ensure all household members are fully vaccinated (cocooning strategy)	Protect the immunocompromised child through herd immunity within the household

Live Vaccines in STAT3-HIES

The blanket avoidance of live vaccines in STAT3-HIES is somewhat debated. Unlike SCID (where live vaccines are absolutely contraindicated), STAT3-HIES patients have intact total T-cell numbers and function — the defect is primarily in Th17 cells. Some centres cautiously allow live vaccines (especially MMR and varicella) if CD4 counts are adequate, because the risk of natural measles or varicella is likely greater than vaccine-strain infection. However, for exam purposes, the safest answer is: avoid live vaccines in patients with primary immunodeficiency unless specifically cleared by the immunology team.

Pillar	Interventions
1. Antimicrobial prophylaxis	Septrin (TMP-SMX) lifelong + Itraconazole (antifungal) lifelong ^[2]
2. Immunoglobulin replacement	IVIG (or SCIG) if specific antibody deficiency demonstrated ^[2]
3. Biologics	Secukinumab (anti-IL-17A) ^[2]; dupilumab (anti-IL-4Rα) for refractory eczema
4. Skin care	Emollients, topical steroids, bleach baths, topical calcineurin inhibitors
5. Acute infection treatment	Anti-Staph antibiotics, antifungals (voriconazole for Aspergillus), surgical I&D
6. Dental	Extraction of retained primary teeth, regular dental surveillance
7. Skeletal	Calcium/vitamin D, DEXA monitoring, bisphosphonates if needed, scoliosis monitoring
8. Vascular	Echo + MRA screening in adolescence
9. HSCT	Not standard; case-by-case for severe refractory disease
10. Family-centred care	Genetic counselling, family screening, psychosocial support, vaccination planning, transition planning

High Yield Summary — Management of STAT3-HIES

Treatment triad from lectures: Septrin + IVIG + Secukinumab ^[2]
Septrin (TMP-SMX): Lifelong; covers Staph aureus + PJP; paediatric suspension available
Itraconazole: Lifelong antifungal prophylaxis; covers Aspergillus (fluconazole does NOT)
IVIG: Indicated if specific antibody deficiency or recurrent infections despite Septrin; 400–600 mg/kg every 3–4 weeks
Dupilumab: Emerging as effective for refractory eczema; blocks IL-4/IL-13; reduces IgE
Acute Staph abscess: I&D + anti-staphylococcal antibiotics; CRP may be misleadingly low
Invasive aspergillosis: Voriconazole first-line; liposomal amphotericin B alternative
Dental: Extract retained primary teeth to allow permanent teeth to erupt
Skeletal: Calcium/vitamin D, DEXA monitoring, bisphosphonates for recurrent fractures
HSCT is NOT standard for STAT3-HIES (unlike DOCK8 deficiency and SCID where HSCT is recommended)
Avoid live vaccines unless specifically cleared by immunology
Never rely on CRP to gauge infection severity in STAT3-HIES patients

Active Recall - Management of STAT3-HIES

References

Complications of STAT3 Hyper-IgE Syndrome

STAT3-HIES is a multisystem disease, so its complications span virtually every organ system. It is helpful to organise complications into two broad categories that mirror the pathophysiology:

Complications arising from the immunological defect — infections and their sequelae
Complications arising from the non-immunological (connective tissue/skeletal/vascular) defect — structural and degenerative

A third, increasingly recognised category is:

Complications related to immune dysregulation — autoimmunity and malignancy

From the lecture notes ^[2]: "Remember that immunodeficiency not just infection susceptible, also increased risk for autoimmune diseases, malignancy etc." This principle applies to STAT3-HIES — the complications extend far beyond infections alone.

2. Pulmonary Complications

These are the major driver of morbidity and mortality in STAT3-HIES. The lung is the organ most severely affected because it is the convergence point of the immunological defect (Th17 deficiency → recurrent pneumonia) and the tissue remodelling defect (STAT3 → MMP dysregulation → impaired repair).

Feature	Detail
Definition	Persistent thin-walled, air-filled cystic cavities in the lung parenchyma that form after episodes of pneumonia
Pathophysiology	Bacterial pneumonia → parenchymal necrosis and destruction → in a normal host, the lung repairs itself via controlled extracellular matrix remodelling (involving MMPs regulated by STAT3) → in STAT3-HIES, impaired STAT3 signalling → dysregulated MMP activity → failure of normal lung repair → cystic cavity persists and becomes permanent
Clinical significance	Pneumatoceles are the hallmark pulmonary complication of STAT3-HIES ^[2]; once formed, they do not resolve spontaneously
Key risk	Pneumatoceles create a "dead space" that is poorly ventilated and poorly perfused → becomes a nidus for secondary colonisation and superinfection

Why Pneumatoceles Are So Dangerous

Think of a pneumatocele as a permanent "cave" inside the lung. It has no normal mucociliary clearance, no normal blood supply, and no normal immune cell patrolling. Organisms that land there are extremely difficult to eradicate. This is why pneumatoceles become chronically colonised — and why STAT3-HIES patients can develop life-threatening superinfections years after the original pneumonia episode.

Organism	Clinical Presentation	Why This Organism?
Pseudomonas aeruginosa	Chronic productive cough, purulent sputum, fevers; air-fluid levels within cysts on imaging	Pseudomonas thrives in stagnant, poorly cleared environments (same reason it infects cystic fibrosis lungs)
Aspergillus fumigatus	Invasive pulmonary aspergillosis (IPA) — fever unresponsive to antibiotics, haemoptysis, pleuritic pain; "air-crescent sign" or halo sign on CT	Th17/IL-22 deficiency → impaired antifungal epithelial defence; pneumatocele cavities provide an ideal environment for fungal hyphae to grow
Non-tuberculous mycobacteria (NTM)	Chronic indolent infection; low-grade fevers, weight loss, progressive lung destruction	NTM (M. avium complex, M. abscessus) colonise damaged lung parenchyma
Staphylococcus aureus	Ongoing bacterial pneumonia	Same Th17 deficiency that caused the original pneumonia

Invasive aspergillosis superinfecting pneumatoceles is one of the leading causes of death in STAT3-HIES ^[2]. This is why lifelong itraconazole prophylaxis is essential once pneumatoceles develop.

Feature	Detail
Pathophysiology	Recurrent lower respiratory infections → chronic airway inflammation → destruction of bronchial wall elastic tissue and smooth muscle → permanent bronchial dilatation
Clinical features	Chronic productive cough with purulent sputum, recurrent exacerbations, haemoptysis, progressive decline in lung function
Why irreversible?	Once the bronchial wall structure is destroyed, it cannot regenerate (unlike reversible bronchospasm in asthma). The dilated airways pool secretions → further infection → further destruction → vicious cycle
Management	Airway clearance physiotherapy, long-term macrolide (azithromycin for anti-inflammatory effect), prompt treatment of exacerbations, IVIG optimisation

Rupture of a peripheral pneumatocele into the pleural space → air leak → bronchopleural fistula and/or pneumothorax
May present acutely with sudden pleuritic chest pain and dyspnoea
Requires chest drain insertion; may need surgical repair for persistent air leak

The cumulative burden of pneumatoceles, bronchiectasis, superinfections, and progressive parenchymal destruction can lead to chronic respiratory failure in adolescence or early adulthood
Some patients eventually require lung transplantation — though this is complicated by their underlying immunodeficiency

While the lungs bear the brunt, infections can affect virtually any organ:

Infection	Mechanism	Clinical Importance
Recurrent skin and soft tissue infections	Th17 deficiency → impaired cutaneous antimicrobial defence → Staph aureus colonisation and invasion ^[2]	"Cold" abscesses → scarring, disfigurement; risk of secondary bacteraemia
Bacteraemia/sepsis	Extension from skin or pulmonary infections; also from line-related infections	Risk of septic shock — worsened by impaired acute phase response (CRP may not rise)
Chronic mucocutaneous candidiasis	Th17/IL-22 deficiency → impaired epithelial antifungal peptide production	Oral candidiasis may impair nutrition; oesophageal candidiasis → dysphagia; nail candidiasis → dystrophy
Invasive fungal infections	Beyond Aspergillus: Coccidioides, Histoplasma, Cryptococcus, PJP in some cases	Disseminated disease can be fatal; particularly high risk in those not on antifungal prophylaxis
Chronic sinusitis	Impaired mucosal immunity → recurrent bacterial sinus infections → chronic mucosal inflammation and polyp formation	May require endoscopic sinus surgery; impacts quality of life

4. Skeletal Complications

These arise from STAT3's role in bone remodelling via IL-6/IL-11 signalling through osteoblasts and osteoclasts.

Feature	Detail
Pathophysiology	STAT3 LOF → impaired osteoblast/osteoclast coupling → reduced bone mineral density (BMD) → osteopenia/osteoporosis from childhood
Clinical presentation	Fractures with minimal trauma (e.g. falling from standing height, twisting injuries); most commonly long bones and vertebral compression fractures
Paediatric significance	Children should be building peak bone mass during childhood and adolescence; in STAT3-HIES, this is impaired → lifelong skeletal fragility
Management	Calcium/vitamin D supplementation, weight-bearing exercise, DEXA monitoring, bisphosphonates (pamidronate IV) in severe cases

Feature	Detail
Prevalence	Present in up to 60–70% of STAT3-HIES patients
Pathophysiology	Impaired STAT3 signalling in vertebral body and intervertebral disc development → progressive spinal curvature
Clinical significance	May be progressive; severe scoliosis (Cobb angle > 40–50°) can compromise respiratory function (particularly dangerous in a patient who already has pneumatoceles and bronchiectasis)
Management	Annual screening; bracing for moderate curves; surgical correction (spinal fusion) for severe progressive curves

Premature fusion of cranial sutures → abnormal skull shape
Rare but reported in STAT3-HIES
May require neurosurgical intervention if causing raised intracranial pressure

Connective tissue laxity → recurrent joint sprains, subluxations
Over time, may develop premature degenerative joint disease due to chronic instability

Complication	Pathophysiology	Clinical Impact
Retained primary teeth	IL-11 → STAT3 → osteoclast activation required for root resorption; LOF → roots persist → teeth not shed	Malocclusion, crowding, difficulty eating; requires planned extraction
Dental caries	Chronic candidiasis + enamel abnormalities + difficulty with oral hygiene (due to candidiasis and gum inflammation)	Increased caries burden
Periodontal disease	Impaired mucosal immunity → chronic gingival inflammation	Progressive periodontal destruction if untreated

6. Vascular Complications

These are among the most feared complications because they can cause sudden death, and they become increasingly relevant as patients survive into adolescence and adulthood.

Feature	Detail
Pathophysiology	STAT3 involved in vascular smooth muscle cell maintenance via VEGF/EGF signalling → LOF → vessel wall weakening → aneurysmal dilatation of coronary arteries
Clinical significance	Usually asymptomatic until complication — myocardial infarction (MI) from thrombus formation within the aneurysm or from aneurysm rupture; MI in a teenager or young adult should raise suspicion of underlying vascular disorder
Screening	Echocardiography in adolescence; CT coronary angiography if dilatation detected

Feature	Detail
Pathophysiology	Same vessel wall weakening mechanism as coronary aneurysms, affecting cerebral arteries
Clinical significance	Risk of subarachnoid haemorrhage (SAH) — a neurosurgical emergency with high morbidity and mortality
Screening	MRA brain in adolescence; some centres recommend periodic screening every 3–5 years
Management	If aneurysm detected: neurosurgical or neurointerventional management (coiling or clipping) depending on size and morphology

Generalised tortuosity of medium-sized arteries on angiographic imaging
Reflects the global connective tissue defect
Usually asymptomatic but may complicate vascular access procedures

Vascular Complications — A Cause of Premature Death

Historically, STAT3-HIES patients died primarily from pulmonary complications (pneumatocele superinfection, respiratory failure). With improved antimicrobial prophylaxis and IVIG, patients are surviving longer — and vascular complications (MI from coronary aneurysm, SAH from cerebral aneurysm) are emerging as important causes of morbidity and mortality in the second and third decades of life. This underscores the importance of vascular surveillance starting in adolescence.

"Immunodeficiency not just infection susceptible, also increased risk for autoimmune diseases, malignancy etc." ^[2]

Malignancy	Association with STAT3-HIES	Mechanism
Non-Hodgkin lymphoma (NHL)	Increased risk; B-cell lymphomas most common	Chronic immune stimulation + impaired immune surveillance (due to STAT3 dysfunction in immune regulation)
Hodgkin lymphoma	Reported in case series	Similar mechanism
Squamous cell carcinoma (SCC)	SCC of the skin, vulva, oral cavity reported	Chronic HPV or other viral infections (less well-controlled due to partial immune deficiency); chronic skin inflammation

The overall malignancy risk in STAT3-HIES is lower than in DOCK8 deficiency (which has a very high malignancy rate, especially SCC and lymphoma)
Nevertheless, lymphoma surveillance (clinical examination for lymphadenopathy, monitoring of LDH, β2-microglobulin) should be part of long-term follow-up

STAT3 is involved in immune regulation (IL-10 → STAT3 pathway is anti-inflammatory). LOF mutations can lead to immune dysregulation and autoimmunity:

Autoimmune Complication	Mechanism	Frequency
Autoimmune cytopenias (AIHA, ITP)	Impaired regulatory T-cell function and B-cell tolerance	Uncommon but reported
Vasculitis	Immune dysregulation affecting vessel walls	Rare
Thyroid autoimmunity	Autoantibodies against thyroid antigens	Rare

Autoimmune complications are less prominent in STAT3-HIES than in some other PIDs (e.g. CVID, IPEX) but should still be considered if unexplained cytopenias or organ-specific autoimmunity develops.

Treatment	Complication	Mechanism
Chronic TMP-SMX	Bone marrow suppression (rare), rash, SJS (very rare), hyperkalaemia	Folate antagonism; idiosyncratic drug reaction
Chronic azole antifungals	Hepatotoxicity, drug interactions (CYP3A4 inhibition)	Direct hepatocyte toxicity; interference with cytochrome P450 metabolism
IVIG	Infusion reactions, anaphylaxis (especially if IgA-deficient with anti-IgA Ab), aseptic meningitis, haemolytic anaemia, thromboembolic events	IgG aggregates trigger complement; passive anti-A/anti-B isoagglutinins
Secukinumab	Worsening of candidiasis (blocking residual IL-17A further impairs anti-Candida defence), injection site reactions	IL-17A blockade → further compromise of already deficient Th17-dependent mucosal defence
Dupilumab	Conjunctivitis, transient eosinophilia	Mechanism not fully understood; possibly redirected eosinophil trafficking
Bisphosphonates	Osteonecrosis of the jaw (rare in children), atypical femoral fractures (very rare), hypocalcaemia	Excessive osteoclast inhibition; calcium redistribution into bone
HSCT (if performed)	Graft-versus-host disease (acute and chronic), graft failure, VOD of liver, infection (CMV, PJP, fungal), second malignancy, infertility	Conditioning regimen toxicity + allogeneic immune mismatch ^[10]

Complication	Detail
Body image	Coarse facies, scarring from recurrent abscesses, scoliosis → significant impact on self-esteem and social integration, particularly in adolescence
School attendance	Recurrent infections, hospitalisations, clinic visits → school absenteeism → academic underperformance
Activity restriction	Risk of pathological fractures → avoidance of contact sports and high-impact activities → social isolation
Chronic disease burden	Daily prophylactic medications, regular IVIG infusions, multiple subspecialty appointments → "treatment fatigue" in both child and family
Parental stress	Managing a rare, lifelong, multisystem condition → caregiver burnout; genetic guilt (especially if inherited from a parent)
Transition challenges	Moving from paediatric to adult services → risk of loss to follow-up; adult physicians less familiar with STAT3-HIES

Family-Centred Care

In paediatric STAT3-HIES management, always remember to address the family as well as the child. Genetic counselling, psychosocial support, school liaison, and planning for transition to adult care are all integral components. The Hong Kong Hospital Authority provides multidisciplinary paediatric immunology services that include clinical psychology and medical social work — utilise these.

System	Complications	Mechanism
Pulmonary	Pneumatoceles → superinfection (Pseudomonas, Aspergillus, NTM) → bronchiectasis → respiratory failure ^[2]	Recurrent pneumonia + impaired tissue repair
Skin	Recurrent "cold" abscesses → scarring; chronic eczema → secondary infection	Th17 deficiency → impaired skin defence
Dental	Retained primary teeth → malocclusion; caries; periodontal disease	IL-11/STAT3 osteoclast defect
Skeletal	Osteoporosis → pathological fractures; scoliosis; craniosynostosis	Impaired bone remodelling
Vascular	Coronary artery aneurysms → MI; cerebral aneurysms → SAH; arterial tortuosity	Impaired VEGF/STAT3 vascular maintenance
Malignancy	Lymphoma (NHL, HL); SCC	Impaired immune surveillance
Autoimmune	AIHA, ITP (uncommon)	Impaired immune regulation (IL-10/STAT3)
Infectious	Bacteraemia/sepsis; invasive fungal disease; chronic sinusitis	Th17 deficiency + impaired acute phase response
Psychosocial	Body image, school absence, activity restriction, caregiver burden	Chronic multisystem disease

High Yield Summary — Complications of STAT3-HIES

Pneumatoceles are the hallmark complication — they form after pneumonia due to impaired lung repair and become chronically superinfected with Pseudomonas, Aspergillus, and NTM
Invasive aspergillosis superinfecting pneumatoceles is a leading cause of death — hence lifelong itraconazole prophylaxis
Bronchiectasis develops from recurrent lower respiratory infections → chronic productive cough, progressive lung function decline
Pathological fractures from osteoporosis (impaired STAT3 → bone remodelling defect) — fractures with minimal trauma in a child should raise suspicion
Scoliosis in up to 60–70% — may compromise respiratory function in a patient already with pneumatoceles
Retained primary teeth — require planned dental extraction
Coronary and cerebral aneurysms — emerging as important causes of mortality in adolescence/adulthood; screen with echo and MRA
Lymphoma (NHL > HL) — immunodeficiency increases malignancy risk
Psychosocial impact — coarse facies, scars, chronic disease burden → address body image, school, family support
Treatment complications — monitor for TMP-SMX marrow suppression, azole hepatotoxicity, IVIG reactions, secukinumab-induced candidiasis worsening

Active Recall - Complications of STAT3-HIES

References

^[1] Lecture slides: GC 144. A child with recurrent infections Primary immunodeficiencies.pdf ^[2] Senior notes: Jerry's immunodeficiencies.pdf (Block A and Block C sections) ^[3] Lecture slides: Investigations of Imm Disorders 2025.pdf ^[7] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (p1790 — atopic eczema complications for comparison) ^[10] Senior notes: Ryan Ho Haemtology.pdf (p156 — HSCT complications)

High Yield Summary

STAT3 Hyper-IgE Syndrome (STAT3-HIES / Job Syndrome)

Definition: Autosomal dominant, loss-of-function (dominant-negative) mutation in STAT3 → multisystem PID with syndromic features
IUIS Category: Combined immunodeficiency with associated/syndromic features (Category 2)
Core Immunological Defect: Th17 deficiency → susceptibility to Staph aureus (cold abscesses), fungi (Candida, Aspergillus)
Classic Triad: Recurrent cold Staph abscesses + Recurrent pneumonia with pneumatoceles + Markedly elevated IgE
Key Lab Findings: IgE > 2000 IU/mL, eosinophilia, low Th17 cells, CXR pneumatoceles
Syndromic Features: Coarse facies, retained primary teeth, scoliosis, pathological fractures, joint hyperextensibility, vascular aneurysms
Why "cold" abscesses? → IL-6/STAT3 impairment → poor acute phase response → poor neutrophil chemotaxis → muted inflammation
Why pneumatoceles? → Impaired tissue repair post-pneumonia (STAT3 involved in wound healing/MMP regulation)
Why retained teeth? → IL-11/STAT3 → osteoclast activation for root resorption impaired
Treatment: Prophylactic antibiotics (TMP-SMX) + antifungals (itraconazole/voriconazole) + IVIG + consider secukinumab; skin care; dental extraction of retained teeth; fracture prevention
Key Distinction: STAT3-HIES (AD) has pneumatoceles and skeletal features; DOCK8 deficiency (AR) has severe viral infections — do NOT confuse them

High Yield Summary — Differential Diagnosis of STAT3-HIES

DOCK8 deficiency (AR-HIES): The #1 differential. Distinguished by severe viral infections (molluscum, HPV, HSV), food allergy, NO pneumatoceles, NO skeletal features. HSCT is curative.
Wiskott-Aldrich syndrome: Eczema + micro-thrombocytopenia (small platelets) + immunodeficiency ± bloody diarrhoea. X-linked.
Chronic granulomatous disease: "Hot" abscesses, granulomas, BCG dissemination, hepatosplenomegaly, normal IgE. Phagocyte NADPH oxidase defect.
Leukocyte adhesion deficiency: Markedly elevated neutrophils, delayed cord separation, omphalitis, absent pus. CD18 defect.
SCID: Severe, early-onset, all infections, profound lymphopenia, absent thymic shadow, low all immunoglobulins.
Severe atopic eczema: Most common misdiagnosis. Distinguished by: flexural distribution, atopic triad, allergic comorbidities, NO pneumatoceles, NO skeletal features, less dramatically elevated IgE.
Hyper-IgM syndrome: High IgM, low IgG/IgA/IgE (opposite pattern to HIES).
NIH HIES score ≥ 40 + low Th17 cells + STAT3 mutation = definitive diagnosis.

High Yield Summary — Diagnosis of STAT3-HIES

No single diagnostic criterion — use clinical phenotype + NIH score + Th17 quantification + genetic confirmation
First-line CBC findings for PIDs (GC high yield): Low ALC → SCID; High AEC → HIES/atopic; Low PLT → WAS; High ANC → LAD; High IgE → HIES
IgE typically > 2000 IU/mL but may fluctuate; use highest ever recorded value
Th17 quantification by intracellular IL-17A staining is the most informative immunological test
CXR pneumatoceles are the hallmark radiographic finding
CRP may be inappropriately low during active infection (impaired IL-6 → STAT3 → CRP pathway)
Genetic testing (STAT3 sequencing) is the gold standard for definitive diagnosis
DHR assay should be normal in STAT3-HIES — order it to exclude CGD in children with recurrent Staph infections
NIH score ≥ 40 = highly suggestive; but in young infants, score may be low due to incomplete phenotype development → still test if suspicious
Always consult immunology when clinically suspicious — many IEIs cannot be picked up by initial screening tests

High Yield Summary — Management of STAT3-HIES

Treatment triad from lectures: Septrin + IVIG + Secukinumab ^[2]
Septrin (TMP-SMX): Lifelong; covers Staph aureus + PJP; paediatric suspension available
Itraconazole: Lifelong antifungal prophylaxis; covers Aspergillus (fluconazole does NOT)
IVIG: Indicated if specific antibody deficiency or recurrent infections despite Septrin; 400–600 mg/kg every 3–4 weeks
Dupilumab: Emerging as effective for refractory eczema; blocks IL-4/IL-13; reduces IgE
Acute Staph abscess: I&D + anti-staphylococcal antibiotics; CRP may be misleadingly low
Invasive aspergillosis: Voriconazole first-line; liposomal amphotericin B alternative
Dental: Extract retained primary teeth to allow permanent teeth to erupt
Skeletal: Calcium/vitamin D, DEXA monitoring, bisphosphonates for recurrent fractures
HSCT is NOT standard for STAT3-HIES (unlike DOCK8 deficiency and SCID where HSCT is recommended)
Avoid live vaccines unless specifically cleared by immunology
Never rely on CRP to gauge infection severity in STAT3-HIES patients

High Yield Summary — Complications of STAT3-HIES

Pneumatoceles are the hallmark complication — they form after pneumonia due to impaired lung repair and become chronically superinfected with Pseudomonas, Aspergillus, and NTM
Invasive aspergillosis superinfecting pneumatoceles is a leading cause of death — hence lifelong itraconazole prophylaxis
Bronchiectasis develops from recurrent lower respiratory infections → chronic productive cough, progressive lung function decline
Pathological fractures from osteoporosis (impaired STAT3 → bone remodelling defect) — fractures with minimal trauma in a child should raise suspicion
Scoliosis in up to 60–70% — may compromise respiratory function in a patient already with pneumatoceles
Retained primary teeth — require planned dental extraction
Coronary and cerebral aneurysms — emerging as important causes of mortality in adolescence/adulthood; screen with echo and MRA
Lymphoma (NHL > HL) — immunodeficiency increases malignancy risk
Psychosocial impact — coarse facies, scars, chronic disease burden → address body image, school, family support
Treatment complications — monitor for TMP-SMX marrow suppression, azole hepatotoxicity, IVIG reactions, secukinumab-induced candidiasis worsening

STAT3 Hyper-ige Syndrome

STAT3 Hyper-IgE Syndrome (STAT3-HIES / Job Syndrome / Autosomal Dominant Hyper-IgE Syndrome)

4. Anatomy and Function: The STAT3 Signalling Pathway

5. Aetiology and Pathophysiology

5.2 Pathophysiology: Connecting Genotype to Phenotype

6. Classification

7. Clinical Features

7.2 Symptoms (with Pathophysiological Basis)

7.3 Signs (with Pathophysiological Basis)

Active Recall - STAT3 Hyper-IgE Syndrome (Definition, Aetiology, Clinical Features)

Differential Diagnosis of STAT3 Hyper-IgE Syndrome

3. Systematic Differential Diagnosis

3.1 Other Primary Immunodeficiencies with Elevated IgE

3.2 Other Causes of Markedly Elevated IgE + Eczema in Children

3.3 Non-Immunological Differentials (Based on Syndromic Features)

Active Recall - Differential Diagnosis of STAT3-HIES

References

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for STAT3 Hyper-IgE Syndrome

1. Diagnostic Criteria

3. Investigation Modalities — Detailed Breakdown

3.1 First-Line Investigations (Available in Any Paediatric Unit)

3.2 Second-Line Investigations (Immunology Laboratory)

3.3 Definitive Investigation: Genetic Testing

Active Recall - Diagnostic Criteria and Investigations of STAT3-HIES

References

Management of STAT3 Hyper-IgE Syndrome

3. Treatment Modalities — Detailed Breakdown

3.1 Antimicrobial Prophylaxis

3.2.1 Intravenous Immunoglobulin (IVIG) [2]

3.4 Targeted Biologic Therapies

Active Recall - Management of STAT3-HIES

References

Complications of STAT3 Hyper-IgE Syndrome

2. Pulmonary Complications

4. Skeletal Complications

6. Vascular Complications

Active Recall - Complications of STAT3-HIES

References

On this page

STAT3 Hyper-ige Syndrome

1. Definition

2. Epidemiology

3. Risk Factors

4. Anatomy and Function: The STAT3 Signalling Pathway

4.1 What is STAT3?

4.2 The JAK-STAT Signalling Pathway (First Principles)

4.3 Cytokines That Signal Through STAT3

4.4 The Central Defect: Th17 Cell Deficiency

4.5 Why IgE Is Elevated

5. Aetiology and Pathophysiology

5.1 Genetic Aetiology

5.2 Pathophysiology: Connecting Genotype to Phenotype

5.2.1 Immunological Consequences

5.2.2 Non-Immunological (Syndromic) Consequences

6. Classification

6.1 Within the IUIS Classification of Inborn Errors of Immunity

6.2 Hyper-IgE Syndromes (HIES) — Broader Classification

7. Clinical Features

7.1 Overview of the Clinical Presentation by Age

7.2 Symptoms (with Pathophysiological Basis)

7.2.1 Immunological Symptoms

7.2.2 Non-Immunological (Syndromic) Symptoms

7.3 Signs (with Pathophysiological Basis)

7.3.1 General Examination

7.3.2 Skin and Mucous Membrane Examination

7.3.3 Dental Examination

7.3.4 Musculoskeletal Examination

7.3.5 Respiratory Examination

7.3.6 Vascular Examination (More Relevant in Adolescents/Young Adults)

7.4 NIH HIES Scoring System

7.5 Summary Table: Immunological vs Non-Immunological Features

7.6 Investigations Relevant to Clinical Features (Preview)

8. Hong Kong–Specific Considerations

Active Recall - STAT3 Hyper-IgE Syndrome (Definition, Aetiology, Clinical Features)

References

1. Why Differential Diagnosis Is Challenging

2. Differential Diagnosis Algorithm (Mermaid Diagram)

3. Systematic Differential Diagnosis

3.1 Other Primary Immunodeficiencies with Elevated IgE

3.1.1 DOCK8 Deficiency (Autosomal Recessive Hyper-IgE Syndrome)

3.1.2 Wiskott-Aldrich Syndrome (WAS)

3.1.3 Chronic Granulomatous Disease (CGD)

3.1.4 Leukocyte Adhesion Deficiency (LAD)

3.1.5 Severe Combined Immunodeficiency (SCID)

3.1.6 Hyper-IgM Syndrome (HIGM)

3.2 Other Causes of Markedly Elevated IgE + Eczema in Children

3.2.1 Severe Atopic Dermatitis (Atopic Eczema)

3.2.2 Omenn Syndrome (Leaky SCID)

3.2.3 IPEX Syndrome (Immune dysregulation, Polyendocrinopathy, Enteropathy, X-linked)

3.3 Non-Immunological Differentials (Based on Syndromic Features)

3.3.1 Ehlers-Danlos Syndrome / Marfan Syndrome

3.3.2 Loeys-Dietz Syndrome

4. Summary Table: Key Differentials of STAT3-HIES

5. Approach to Narrowing the Differential

Active Recall - Differential Diagnosis of STAT3-HIES

1. Diagnostic Criteria

1.1 NIH HIES Clinical Scoring System (Grimbacher et al., Updated)

1.2 Practical Diagnostic Criteria (Consensus Approach, 2020s)

2. Diagnostic Algorithm

3. Investigation Modalities — Detailed Breakdown

3.1 First-Line Investigations (Available in Any Paediatric Unit)

3.1.1 Complete Blood Count with Differential (CBC with D/C)

3.1.2 Serum Immunoglobulins (IgG, IgA, IgM, IgE)

3.1.3 Chest X-Ray (CXR)

3.1.4 Inflammatory Markers (CRP, ESR)

3.1.5 Microbiological Investigations (Culture and Sensitivity)

3.2 Second-Line Investigations (Immunology Laboratory)

3.2.1 Lymphocyte Subsets (T, B, NK Cell Enumeration by Flow Cytometry)

3.2.2 Th17 Cell Quantification (Intracellular Cytokine Staining)

3.2.3 Specific Antibody Responses to Vaccines

3.2.4 DHR (Dihydrorhodamine) Assay / NBT (Nitroblue Tetrazolium) Test

3.3 Definitive Investigation: Genetic Testing

3.3.1 STAT3 Gene Sequencing

3.3.2 STAT3 Phosphorylation Assay (Functional Confirmation)

3.4 Adjunctive / Monitoring Investigations

4. Summary: Investigation Pathway for Suspected STAT3-HIES

Active Recall - Diagnostic Criteria and Investigations of STAT3-HIES

1. Principles of Management

2. Management Algorithm